🔗

Mappings

MONDO

MONDO:0009749 giant axonal neuropathy 1

MONDO:0000128 giant axonal neuropathy Not Yet Curated

👪

Inheritance

1

Autosomal recessive inheritance HP:0000007

GAN-related neuropathy is inherited in an autosomal recessive manner; each sib of an affected individual has a 25% chance of inheriting biallelic pathogenic variants.

Autosomal recessive inheritance

Show evidence (1 reference)

PMID:20301315 SUPPORT Human Clinical

"GAN-related neuropathy is inherited in an autosomal recessive manner."

GeneReviews states the mode of inheritance directly.

◆

Subtypes

2

Classic giant axonal neuropathy (severe, PNS plus CNS)

The severe end of the continuum. Infantile-onset severe peripheral motor and sensory neuropathy evolving into central nervous system impairment (intellectual disability, seizures, cerebellar signs and pyramidal tract signs), with wheelchair dependence in the second decade and death usually in the third decade.

Show evidence (2 references)

PMID:20301315 SUPPORT Human Clinical

"The classic giant axonal neuropathy phenotype typically manifests as an infantile-onset neurodegenerative disorder, starting as a severe peripheral motor and sensory neuropathy and evolving into central nervous system impairment (intellectual disability, seizures, cerebellar signs, and pyramidal..."

GeneReviews defines the classic severe phenotype at this end of the continuum.

PMID:39680150 SUPPORT Human Clinical

"From the 15 patients described here, 13 (86.7%) had a classical and one a mild CMT-like phenotype."

Quantifies the predominance of the classic phenotype over the CMT-like phenotype in a systematically ascertained cohort.

Milder CMT-like giant axonal neuropathy (predominantly peripheral)

The mild end of the continuum: predominantly motor and sensory neuropathy with little to no CNS involvement, overlapping clinically with the axonal forms of Charcot-Marie-Tooth neuropathy, and later-onset and slower-progressing than the classic phenotype. Identified as a distinct subcohort in the largest reported natural history cohort. Same genetic mechanism as classic GAN — biallelic GAN loss of function — so this is a phenotypic, not a mechanistic, division.

Show evidence (2 references)

PMID:20301315 SUPPORT Human Clinical

"At the milder end of the spectrum are predominantly motor and sensory neuropathies (with little to no CNS involvement) that overlap with the axonal form of Charcot-Marie-Tooth neuropathies."

GeneReviews defines the mild end of the phenotypic continuum.

PMID:34114613 SUPPORT Human Clinical

"Importantly, we identified and characterized a subcohort of individuals with a milder form of GAN and with a presentation similar to Charcot-Marie-Tooth disease."

The natural history cohort independently identifies and characterizes this subcohort as distinct from the classic presentation.

?

Discussions and Knowledge Gaps

2

Does the preclinical evidence base for GAN - built largely on Gan-knockout mice that lack giant axons and neurofilament compaction - support inference about the human disease, and does the A49E knock-in change what earlier knockout results can be taken to show?

HUMAN MODEL MISMATCH gan_knockout_model_fidelity

Attached to

pathophysiology#Giant Axon Formation

The gene-transfer work that supported the first-in-human trial was performed largely in knockout strains now reported to lack the two defining human lesions. That is a translational-validity question rather than a gap in evidence: the mouse results exist and are internally sound, but the model was missing the pathology the therapy is meant to reverse. The A49E knock-in reproduces those lesions and so offers a way to test whether the earlier conclusions hold. Its female-biased severity has no established human counterpart and should not be carried into human claims.

Proposed experiments

Replicate intrathecal AAV9 GAN gene transfer in the A49E knock-in

gan_a49e_gene_transfer_replication

Repeat the preclinical intrathecal scAAV9/JeT-GAN dosing in GAN A49E/A49E mice and score giant axon burden and neurofilament compaction - endpoints unavailable in the knockout strains - alongside the rotarod and nerve ultrastructure measures used originally, powered to detect the reported sex difference.

Show evidence (1 reference)

PMID:41402936 SUPPORT Model Organism

"Unlike previous GAN knock-out mice which show no overt phenotype, GANA49E/A49E mice exhibit early sensory-motor deficits and ataxia"

States the contrast between the knockout strains and the knock-in that makes this a model-fidelity question.

What determines position on the GAN phenotypic continuum — why do some individuals with biallelic GAN loss-of-function variants develop classic infantile multisystem neurodegeneration while others have a milder, later-onset, predominantly peripheral CMT-like course?

KNOWLEDGE GAP gan_phenotypic_continuum_determinants

Attached to

pathophysiology#Progressive Neurological Decline

Both ends of the continuum share the same causal mechanism — biallelic GAN loss of function — yet differ markedly in age of onset, rate of progression, and whether the central nervous system is involved at all. The natural history cohort characterized the milder subcohort but the determinants of that divergence (residual gigaxonin function by genotype, modifier alleles, or another factor) are not established, which matters directly for prognosis and for trial stratification. The obvious candidate explanation — genotype — has been looked for and not found: no mutation hotspot exists and no apparent genotype-phenotype correlation has been demonstrated, so this is an open question rather than an unexamined one.

Proposed experiments

Genotype-to-continuum-position correlation in the natural history cohort

gan_genotype_continuum_correlation

Correlate genotype class (null/null versus genotypes predicted to retain residual gigaxonin, e.g. missense) with continuum position and rate of MFM-32 decline in the prospective natural history cohort, using cross-reactive immunologic material status as an independent measure of residual protein.

Show evidence (1 reference)

PMID:39680150 SUPPORT Human Clinical

"An obvious mutation hotspot does not exist, and there is no apparent correlation between genotype and phenotype."

Establishes that the genotype-based explanation for continuum position has been sought and not found, which is what makes this a genuine knowledge gap rather than an unasked question.

⚙

Pathophysiology

9

Gigaxonin Loss of Function

Biallelic loss-of-function variants in GAN (16q23.2) abolish functional gigaxonin, the substrate-specific adaptor that recruits intermediate filament proteins to a cullin-3 ubiquitin ligase complex. Gigaxonin is a ubiquitously expressed, low-abundance protein composed of an N-terminal BTB domain followed by six kelch repeats.

gigaxonin substrate-adaptor activity in a cullin-3 ubiquitin ligase complex GO:0031625 ⇓ LOSS OF FUNCTION

Downstream

Impaired Intermediate Filament Degradation

Intermediate Filament Transport Failure

Show evidence (2 references)

PMID:11062483 SUPPORT Human Clinical

"Gigaxonin is composed of an amino-terminal BTB (for Broad-Complex, Tramtrack and Bric a brac) domain followed by a six kelch repeats, which are predicted to adopt a beta-propeller shape."

The gene-discovery paper establishes the domain architecture of gigaxonin that underlies its adaptor role.

PMID:34114613 SUPPORT Human Clinical

"The disease is caused by biallelic mutations in the GAN gene located on 16q23.2, leading to loss of functional gigaxonin, a substrate specific ubiquitin ligase adapter protein necessary for the regulation of intermediate filament turnover."

States the causal genetic lesion, its locus, and the molecular role of the lost protein.

Impaired Intermediate Filament Degradation

Without gigaxonin-directed ubiquitination, intermediate filament proteins escape proteasomal turnover. Gigaxonin controls degradation of the entire intermediate filament family — vimentin in fibroblasts, and peripherin and neurofilament proteins in neurons — and proteasome inhibition reverses the clearance produced by gigaxonin overexpression, placing the defect in the ubiquitin-proteasome pathway.

proteasomal degradation of intermediate filament proteins GO:0043161 ↓ DECREASED protein polyubiquitination of intermediate filament substrates GO:0000209 ↓ DECREASED

Downstream

Intermediate Filament Aggregation

Show evidence (6 references)

PMID:23585478 SUPPORT In Vitro

"Gigaxonin was similarly involved in the degradation of peripherin and neurofilament IF proteins in neurons."

The cell-based arm - gigaxonin-dependent degradation of the neuronal intermediate filament substrates.

PMID:23585478 SUPPORT Model Organism

"Using fibroblasts from patients and normal individuals, as well as Gan-/- mice, we demonstrated that gigaxonin was responsible for the degradation of vimentin IFs."

The same finding established in the Gan-knockout mouse. Split from the in vitro item above so each evidence item carries a single evidence_source, per the mixed-source rule.

PMID:23585478 SUPPORT In Vitro

"Furthermore, proteasome inhibition by MG-132 reversed the clearance of IF proteins in cells overexpressing gigaxonin, demonstrating the involvement of the proteasomal degradation pathway."

Establishes that the degradation route is proteasomal, which is what makes loss of the adaptor sufficient to cause accumulation.

+ 3 more references

Intermediate Filament Transport Failure

Beyond failed degradation, loss of gigaxonin dramatically inhibits kinesin-1-driven transport of intermediate filaments along microtubules. The defect is selective — other kinesin-1 cargoes apart from mitochondria move normally — and forcing kinesin-1 to bind filaments directly rescues their distribution, which places transport failure upstream of the abnormal distribution rather than downstream of it. A more than 20-fold rise in soluble vimentin oligomers accompanies the block.

kinesin-1-driven microtubule-based transport of intermediate filaments GO:0099111 ↓ DECREASED

Downstream

Intermediate Filament Aggregation

Show evidence (2 references)

PMID:37043392 SUPPORT In Vitro

"We have demonstrated that the loss of gigaxonin dramatically inhibited transport of IFs along microtubules by the microtubule motor kinesin-1. This inhibition was specific for IFs, as other kinesin-1 cargoes, with the exception of mitochondria, were transported normally."

Establishes the transport defect and its selectivity for intermediate filaments.

PMID:37043392 SUPPORT In Vitro

"Abnormal distribution of IFs in the cytoplasm can be rescued by direct binding of kinesin-1 to IFs, demonstrating that transport inhibition is the primary cause for the abnormal IF distribution."

The rescue experiment is what makes transport failure causal rather than a secondary consequence of aggregation.

Intermediate Filament Aggregation

Undegraded intermediate filaments accumulate as disorganized aggregates. Because gigaxonin is ubiquitously expressed, the aggregation is generalized and tissue-specific: vimentin in endothelial cells, Schwann cells and cultured skin fibroblasts, GFAP in astrocytes, neurofilaments and peripherin in neurons, and — the likely basis of the hair phenotype — keratins.

dermal fibroblast CL:0000057 astrocyte CL:0000127 sensory neuron of dorsal root ganglion CL:1001451

disorganization of the intermediate filament cytoskeleton GO:0045104 ⚠ ABNORMAL intermediate filament inclusion body formation GO:0070841 ↑ INCREASED

Experimental models

GAN patient dermal fibroblasts (vimentin aggregate assay) PRIMARY CELL CULTURE Patient-derived cells reproduce the defining cellular lesion in the patient's own genetic background.

Animal models

Gan knockout mouse Mouse partially recapitulates The knockout reproduces intermediate filament accumulation and peripheral nerve pathology, and these are reversible by GAN gene transfer, which is what made it usable for preclinical gene-transfer work.

Downstream

Giant Axon Formation

Central Nervous System Degeneration

Autophagy-Lysosome Failure

Show evidence (2 references)

PMID:11062483 SUPPORT Human Clinical

"GAN corresponds to a generalized disorganization of the cytoskeletal intermediate filaments (IFs), to which neurofilaments belong, as abnormal aggregation of multiple tissue-specific IFs has been reported: vimentin in endothelial cells, Schwann cells and cultured skin fibroblasts, and glial..."

Establishes that the aggregation is generalized across cell types rather than restricted to neurons.

PMID:23585478 SUPPORT In Vitro

"In GAN, aggregates of intermediate filaments (IFs) represent the main pathological feature detected in neurons and other cell types, including patients' dermal fibroblasts."

Identifies intermediate filament aggregates as the principal cellular lesion, including in accessible patient fibroblasts.

Autophagy-Lysosome Failure

A secondary, feed-forward consequence of the accumulation rather than a parallel cause of it. Neurofilament accumulations disrupt autophagy by two distinct routes: they interfere with the distribution of autophagic organelles, impairing maturation and fusion with lysosomes; and they sequester the chaperone 14-3-3, which is required for correct localization of the master autophagy regulator TFEB. Because degradative capacity is itself degraded, the arm feeds back onto the accumulation that produced it.

autophagosome-lysosome fusion GO:0061909 ↓ DECREASED

Downstream

Intermediate Filament Aggregation The feed-forward limb: loss of autophagic-lysosomal degradative capacity compounds the accumulation that caused it. Curated as indirect because the source demonstrates the autophagy defect and proposes its contribution to pathogenesis rather than measuring the return effect on filament load.

Show evidence (2 references)

PMID:40059823 SUPPORT Model Organism

"Using a combination of genetic and RNA interference approaches, we found that dorsal root ganglia from mice lacking gigaxonin have impaired autophagy and lysosomal degradation through 2 mechanisms."

Establishes the autophagy-lysosome defect in gigaxonin-null dorsal root ganglia and that it operates by two mechanisms.

PMID:40059823 SUPPORT Model Organism

"First, neurofilament accumulations interfere with the distribution of autophagic organelles, impairing their maturation and fusion with lysosomes. Second, the accumulations attract the chaperone 14-3-3, which is responsible for the proper localization of the key autophagy regulator transcription..."

Names both routes and, critically, their direction - the accumulations act on autophagy, not the reverse.

Giant Axon Formation

In axons the accumulating intermediate filaments produce the pathognomonic focal swellings — segmental distension of the axon densely packed with disorganized neurofilaments — that give the disease its name.

neurofilament cytoskeleton organization GO:0060052 ⚠ ABNORMAL

Animal models

GAN A49E knock-in mouse Mouse recapitulates Reproduces the pathognomonic lesion - giant axons with compacted, disorganized neurofilaments - which the knockout strains do not.

Downstream

Distal Axonal Degeneration Curated as indirect with unknown intermediates rather than DIRECT: giant axons and axonal loss both follow intermediate filament accumulation, and whether the swellings themselves cause the degeneration or are a parallel manifestation of the same underlying accumulation is not established.

Show evidence (2 references)

PMID:11062483 SUPPORT Human Clinical

"Giant axonal neuropathy (GAN, MIM 256850), a severe, autosomal recessive sensorimotor neuropathy affecting both the peripheral nerves and the central nervous system, is characterized by neurofilament accumulation, leading to segmental distension of the axons."

Describes the defining axonal lesion and its neurofilament basis.

PMID:29766026 SUPPORT Other

"The pathologic signature of GAN is giant axonal swellings filled with disorganized accumulations of IFs."

States the pathognomonic finding explicitly.

Central Nervous System Degeneration

The central arm of the disease, parallel to peripheral axonal degeneration rather than downstream of it. Intermediate filament aggregation in central neurons and in astrocytes (where GFAP is the accumulating filament) is accompanied by inclusion bodies in brain, neuroinflammation, and loss of cortical and spinal neurons, and appears radiologically as periventricular and cerebellar white-matter T2 hyperintensity. This is the route by which cerebellar signs, pyramidal signs and cognitive decline arise; they are not consequences of distal peripheral axon loss.

astrocyte CL:0000127

neuronal apoptosis in cortex and spinal cord GO:0051402 ↑ INCREASED

Downstream

Progressive Neurological Decline

Show evidence (4 references)

PMID:34114613 SUPPORT Human Clinical

"presents as a prominent sensorimotor neuropathy and commonly progresses to affect both the PNS and CNS"

Establishes in a human cohort that central nervous system involvement is a distinct feature of the disease course, not merely a description of the peripheral neuropathy.

PMID:39680150 SUPPORT Human Clinical

"Magnetic resonance imaging (MRI) shows high signals on T2-weighted sequences in the anterior and posterior periventricular regions as well as in the cerebellar white matter, sometimes referred to as leukoencephalopathy or leukodystrophy."

The radiological correlate of central white-matter involvement in human patients.

PMID:37137704 SUPPORT Model Organism

"Abundant inclusion bodies composed of disorganized IFs were also detected in the brain of Gan-/-;TgPer mice."

Shows central intermediate filament inclusion pathology in brain, the mechanistic link between the aggregation node and CNS disease.

+ 1 more reference

Distal Axonal Degeneration

Peripheral axonal loss follows, producing the progressive, nerve length-dependent sensorimotor neuropathy that dominates early disease. This is the final common pathway shared with other axonal neuropathies; in GAN the upstream driver is intermediate filament aggregation rather than a primary transport or myelin lesion.

myelinating Schwann cell CL:0000218

axon ensheathment by myelinating Schwann cells GO:0008366 ↓ DECREASED neuronal apoptosis following axonal loss GO:0051402 ↑ INCREASED

Downstream

Progressive Neurological Decline

Show evidence (2 references)

PMID:38507752 SUPPORT Human Clinical

"Peripheral axonal loss in giant axonal neuropathy causes progressive sensorimotor neuropathy, as indicated on electrophysiological testing and histologic analysis of the peripheral nerves."

States the axonal-loss-to-neuropathy step this node asserts, with the electrophysiological and histological basis for it.

PMID:23316953 SUPPORT In Vitro

"On a cellular level GAN is characterized by intermediate filament (IF) aggregation, leading to a progressive and fatal peripheral neuropathy in humans."

Links the cellular aggregation lesion to the progressive peripheral neuropathy. Tagged IN_VITRO because the paper reports patient fibroblast and Gan-knockout mouse experiments, not human clinical data; this sentence is its framing of the disease.

Progressive Neurological Decline

Peripheral neuropathy is joined over time by central nervous system degeneration, giving the polysymptomatic course: cerebellar dysfunction, pyramidal signs, cognitive decline, vision loss, loss of ambulation, and death from pulmonary complications, typically in the third decade.

Show evidence (2 references)

PMID:34114613 SUPPORT Human Clinical

"Giant axonal neuropathy (GAN) is an ultra-rare autosomal recessive, progressive neurodegenerative disease with early childhood onset that presents as a prominent sensorimotor neuropathy and commonly progresses to affect both the PNS and CNS."

Describes the characteristic progression from peripheral to combined peripheral and central involvement.

PMID:20301315 SUPPORT Human Clinical

"Most affected individuals become wheelchair dependent in the second decade of life and eventually bedridden with severe polyneuropathy, ataxia, and dementia. Death usually occurs in the third decade."

GeneReviews states the functional trajectory and life expectancy.

✶

Histopathology

1

Giant axons on nerve biopsy

Electron microscopy of sural nerve shows the pathognomonic lesion: focally enlarged axons distended by densely packed, disorganized intermediate filaments, surrounded by disproportionately thin myelin. Biopsy is now supporting rather than required evidence when molecular testing is definitive.

Show evidence (2 references)

PMID:29766026 SUPPORT Other

"The pathologic signature of GAN is giant axonal swellings filled with disorganized accumulations of IFs."

States the defining histopathological lesion.

PMID:37137704 SUPPORT Human Clinical

"Sural nerve biopsies of human GAN patients have shown the presence of giant axons filled with IFs, a characteristic feature of GAN disease"

States the human sural nerve biopsy finding specifically. The quoted sentence is this paper's summary of the human literature, not its own mouse data, hence HUMAN_CLINICAL.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

24

Digestive 1

Feeding difficulties OCCASIONAL HP:0011968

Show evidence (1 reference)

PMID:39680150 SUPPORT Human Clinical

"Abnormal digestive system physiology6 (40.0) Feeding difficulties4 (26.7)"

HPO-coded frequency row from the German cohort (4 of 15), supporting the OCCASIONAL band.

Eye 2

Vision loss Visual loss HP:0000572

Show evidence (1 reference)

PMID:38507752 SUPPORT Human Clinical

"The disease course includes progressive, nerve length-dependent, sensorimotor neuropathy; cerebellar dysfunction; loss of unassisted independent ambulation by 8 to 10 years of age; vision loss; and secondary systemic complications."

Lists vision loss among the features of the disease course. Bound to HP:0000572 Visual loss, which is exactly what the source states; the underlying ocular lesion is not specified by this evidence, so no more specific term (e.g. optic atrophy) is asserted.

Nystagmus FREQUENT HP:0000639

Show evidence (1 reference)

PMID:39680150 SUPPORT Human Clinical

"Abnormality of the eye9 (60.0) Nystagmus6 (40.0)"

HPO-coded frequency row from the German cohort (6 of 15), supporting the FREQUENT band.

Musculoskeletal 6

Distal muscle weakness VERY_FREQUENT HP:0002460

Course: PROGRESSIVE

Show evidence (1 reference)

PMID:39680150 SUPPORT Human Clinical

"Axial muscle weakness6 (40.0) Distal muscle weakness12 (80.0) Fatigable weakness5 (33.3)"

HPO-coded frequency row from the German cohort (12 of 15), supporting the VERY_FREQUENT band.

Hypotonia VERY_FREQUENT HP:0001252

Show evidence (1 reference)

PMID:39680150 SUPPORT Human Clinical

"Muscular hypotonia14 (93.3) Abnormality of muscle size12 (80.0)"

HPO-coded frequency row from the German cohort (14 of 15), supporting the VERY_FREQUENT band. Note the same paper's running text reports muscle hypotonia in 7 of 15 (46.7%) as a first symptom; the 93.3% figure quoted here is the cohort-wide HPO-coded row from Table 2. The two numbers describe onset versus ever-present and are not a discrepancy.

Scoliosis FREQUENT HP:0002650

Show evidence (1 reference)

PMID:39680150 SUPPORT Human Clinical

"Bone Scoliosis7 (46.7) Abnormality of joint mobility8 (53.3)"

HPO-coded frequency row from the German cohort (7 of 15), supporting the FREQUENT band.

Muscle weakness OBLIGATE HP:0001324

Show evidence (1 reference)

PMID:39680150 SUPPORT Human Clinical

"Muscle Muscle weakness15 (100.0) Generalised muscle weakness5 (33.3)"

HPO-coded frequency row from the German cohort (15 of 15). As with gait disturbance, 15/15 maps to OBLIGATE within this series rather than being a penetrance claim over all reported patients.

Skeletal muscle atrophy FREQUENT HP:0003202

Show evidence (1 reference)

PMID:39680150 SUPPORT Human Clinical

"Abnormality of muscle size12 (80.0) Generalised amyotrophy7 (46.07)"

HPO-coded frequency row from the German cohort. The band is taken from the directly matching "Generalised amyotrophy" row (7 of 15, 46.07%), which supports FREQUENT. The broader "Abnormality of muscle size" row (12 of 15) is not specific to atrophy and so is not used to set the band.

Frequent falls FREQUENT HP:0002359

Show evidence (1 reference)

PMID:39680150 SUPPORT Human Clinical

"Frequent falls10 (66.7) Steppage gait6 (40.0)"

HPO-coded frequency row from the German cohort (10 of 15), supporting the FREQUENT band.

Nervous System 8

Cerebellar dysfunction Progressive cerebellar ataxia HP:0002073

Course: PROGRESSIVE

Show evidence (1 reference)

PMID:20301315 SUPPORT Human Clinical

"evolving into central nervous system impairment (intellectual disability, seizures, cerebellar signs, and pyramidal tract signs)"

GeneReviews lists cerebellar signs among the CNS features of the classic phenotype.

Intellectual disability OCCASIONAL HP:0001249

Show evidence (2 references)

PMID:20301315 SUPPORT Human Clinical

"evolving into central nervous system impairment (intellectual disability, seizures, cerebellar signs, and pyramidal tract signs)"

GeneReviews lists intellectual disability as a CNS feature of the classic phenotype.

PMID:39680150 SUPPORT Human Clinical

"Intellectual disability4 (26.7)Gait Gait disturbance15 (100.0) Gait ataxia5 (33.3)"

HPO-coded frequency row from the German cohort (4 of 15), supporting the OCCASIONAL band and showing that cognitive involvement is not universal even in a predominantly classic-phenotype cohort.

Seizures OCCASIONAL HP:0001250

Show evidence (2 references)

PMID:20301315 SUPPORT Human Clinical

"evolving into central nervous system impairment (intellectual disability, seizures, cerebellar signs, and pyramidal tract signs)"

GeneReviews lists seizures as a CNS feature of the classic phenotype.

PMID:39680150 SUPPORT Human Clinical

"Truncal ataxia3 (20.0) Seizures2 (13.3) Abnormality of the eye9 (60.0)"

HPO-coded frequency row from the German cohort (2 of 15), supporting the OCCASIONAL band.

Gait disturbance OBLIGATE HP:0001288

Show evidence (1 reference)

PMID:39680150 SUPPORT Human Clinical

"Abnormal gait was mentioned in all patients as one of the first symptoms, muscle weakness was notable in 13 (86.7%) patients"

Reports gait abnormality in 15 of 15 patients as a presenting symptom. 15/15 maps to OBLIGATE; the cohort is small (n=15), so this is an obligate finding within the largest systematically ascertained series rather than a claim of 100% penetrance across all patients ever reported.

Areflexia FREQUENT HP:0001284

Show evidence (1 reference)

PMID:39680150 SUPPORT Human Clinical

"Abnormal reflexes12 (80.0) Areflexia11 (73.3) Pyramidal sign2 (13.3)"

HPO-coded frequency row from the German cohort (11 of 15), supporting the FREQUENT band.

Autonomic dysfunction FREQUENT Abnormal autonomic nervous system physiology HP:0012332

Show evidence (1 reference)

PMID:39680150 SUPPORT Human Clinical

"Abnormal autonomic nervous system physiology7 (46.7) Abnormal digestive system physiology6 (40.0)"

HPO-coded frequency row from the German cohort (7 of 15), supporting the FREQUENT band.

Delayed gross motor development OCCASIONAL HP:0002194

Show evidence (1 reference)

PMID:39680150 SUPPORT Human Clinical

"Development Delayed gross motor development4 (26.7) Delayed fine motor development2 (13.3)"

HPO-coded frequency row from the German cohort (4 of 15), supporting the OCCASIONAL band.

Cerebral white matter abnormality Abnormal cerebral white matter morphology HP:0002500

Show evidence (1 reference)

PMID:39680150 SUPPORT Human Clinical

"Magnetic resonance imaging (MRI) shows high signals on T2-weighted sequences in the anterior and posterior periventricular regions as well as in the cerebellar white matter, sometimes referred to as leukoencephalopathy or leukodystrophy."

Describes the white-matter imaging abnormality. No frequency is given by the source, so no frequency band is asserted.

Other 7

Peripheral sensorimotor axonal neuropathy VERY_FREQUENT Peripheral axonal neuropathy HP:0003477

Course: PROGRESSIVE

Show evidence (1 reference)

PMID:34114613 SUPPORT Human Clinical

"Giant axonal neuropathy (GAN) is an ultra-rare autosomal recessive, progressive neurodegenerative disease with early childhood onset that presents as a prominent sensorimotor neuropathy and commonly progresses to affect both the PNS and CNS."

The natural history cohort describes the sensorimotor neuropathy as the presenting feature of the disease. Note this sentence carries no denominator - the VERY_FREQUENT band is a mapping of "presents as a prominent sensorimotor neuropathy" as a defining feature, corroborated by the German cohort's muscle weakness 15/15 and abnormal reflexes 12/15 rows, not a figure quoted from this source.

Tightly curled kinky hair VERY_FREQUENT Curly hair HP:0002212

Show evidence (3 references)

PMID:11062483 SUPPORT Human Clinical

"Keratin IFs also seem to be alterated, as most patients present characteristic curly or kinky hairs."

Reports the hair phenotype and attributes it to the keratin arm of the intermediate filament defect.

PMID:39680150 SUPPORT Human Clinical

"Phenotypic abnormality8 (53.3) Curly/Frizzy hair14 (93.3) Abnormal skull morphology2 (13.3)"

HPO-coded frequency row from the German cohort (14 of 15 patients), supporting the VERY_FREQUENT band.

ORPHA:643 SUPPORT Other

"characteristic kinky hair in most cases"

Orphanet's own definition independently corroborates the hair phenotype as characteristic and present in most patients, agreeing with the German cohort's 93.3% and with the VERY_FREQUENT band.

Sensory ataxia HP:0010871

Show evidence (1 reference)

PMID:38507752 SUPPORT Human Clinical

"Giant axonal neuropathy typically manifests with additional features of dry, tightly curled hair and sensory ataxia in the first few years of life."

States the early presence of sensory ataxia.

Limb joint contractures FREQUENT HP:0003121

Show evidence (1 reference)

PMID:39680150 SUPPORT Human Clinical

"Limb joint contracture8 (53.3) Ankle flexion contracture7 (46.7)"

HPO-coded frequency row from the German cohort (8 of 15), supporting the FREQUENT band.

Respiratory insufficiency requiring ventilatory support OCCASIONAL Respiratory failure requiring assisted ventilation HP:0004887

Show evidence (1 reference)

PMID:39680150 SUPPORT Human Clinical

"Sleep apnoea3 (20.0) Need for ventilatory support2 (13.3)"

HPO-coded frequency row from the German cohort (2 of 15). The band reflects need for ventilatory support at the cross-sectional visit in a cohort of average age 11.7 years, not lifetime risk, which is higher.

Abnormal foot morphology FREQUENT HP:0001760

Show evidence (1 reference)

PMID:39680150 SUPPORT Human Clinical

"Abnormal foot morphology8 (53.3) Talipes4 (26.7) Pes planus7 (46.7)"

HPO-coded frequency row from the German cohort (8 of 15), supporting the FREQUENT band.

Pyramidal signs OCCASIONAL Abnormal pyramidal sign HP:0007256

Show evidence (1 reference)

PMID:39680150 SUPPORT Human Clinical

"Areflexia11 (73.3) Pyramidal sign2 (13.3) Abnormality of coordination7 (46.7)"

HPO-coded frequency row from the German cohort (2 of 15), supporting the OCCASIONAL band. The cohort codes this as the generic "pyramidal sign", which HP:0007256 carries as an exact synonym.

🧬

Genetic Associations

1

GAN

Gene: GAN hgnc:4137 relationship_type: CAUSATIVE

Show evidence (2 references)

PMID:11062483 SUPPORT Human Clinical

"We report here identification of the gene GAN, which encodes a novel, ubiquitously expressed protein we have named gigaxonin. We found one frameshift, four nonsense and nine missense mutations in GAN of GAN patients."

The gene-discovery study identifying GAN and its mutation spectrum in patients.

PMID:34114613 SUPPORT Human Clinical

"We review causative variants distributed throughout the GAN gene in this cohort and identify a recurrent founder mutation in individuals with GAN of Mexican descent as well as cases of recurrent uniparental isodisomy."

Describes the variant distribution, a founder allele, and uniparental isodisomy as a mechanism reaching biallelic status.

💊

Medical Actions

2

Intrathecal scAAV9/JeT-GAN gene transfer

Action: Gene Therapy NCIT:C15238

Self-complementary AAV9 carrying a codon-optimized human GAN transgene under the JeT promoter, delivered by lumbar intrathecal infusion to target spinal motor neuron and dorsal root ganglion cell bodies. Evaluated in a phase 1 dose-escalation study (NCT02362438) in 14 children. Results were mixed and dose-dependent: the 1.8x10^14 vg dose met the prespecified efficacy threshold for slowing motor decline, but the highest dose did not, and adverse events occurred. This is an investigational therapy, not an established standard of care.

Mechanism Target:

RESTORES Gigaxonin Loss of Function — The transgene restores gigaxonin expression, addressing the primary molecular defect rather than a downstream consequence.

Show evidence (1 reference)

PMID:29766026 SUPPORT Model Organism

"This strategy conferred sustained wild-type gigaxonin expression across the PNS and CNS for at least 1 year in mice."

Demonstrates that the vector restores the missing protein, which is the mechanism by which it targets this node.

Show evidence (2 references)

PMID:38507752 SUPPORT Human Clinical

"Intrathecal gene transfer with scAAV9/JeT-GAN for giant axonal neuropathy was associated with adverse events and resulted in a possible benefit in motor function scores and other measures at some vector doses over a year."

The trial's own conclusion is deliberately hedged — possible benefit at some doses, with adverse events — so this supports the treatment only partially.

PMID:38507752 SUPPORT Human Clinical

"Between 6 and 24 months after gene transfer, sensory-nerve action potential amplitudes increased, stopped declining, or became recordable after being absent in 6 participants but remained absent in 8."

Reports the electrophysiological outcome, including the non-responding majority, as an objective measure alongside the motor score.

Multidisciplinary supportive care

Action: Supportive Care NCIT:C15747

No disease-modifying therapy is established. Management is supportive and multidisciplinary, directed at the individual's clinical findings, with the goal of optimizing intellectual and physical development.

Show evidence (1 reference)

PMID:20301315 SUPPORT Human Clinical

"Supportive care is focused on managing the clinical findings of the individual, and often involves a team including neurologists, orthopedic surgeons, physiotherapists, occupational and physical therapists, psychologists, and speech-language pathologists."

GeneReviews management recommendation for the disease.

🔬

Diagnosis

3

Molecular genetic testing

The diagnosis is established in a proband with suggestive clinical findings by identifying biallelic pathogenic GAN variants. Molecular confirmation is now the definitive test, with biopsy relegated to a supporting role.

Show evidence (1 reference)

PMID:20301315 SUPPORT Human Clinical

"The diagnosis of GAN-related neuropathy is established in a proband with suggestive findings and biallelic GAN pathogenic variants identified by molecular genetic testing."

GeneReviews DIAGNOSIS/TESTING statement establishing molecular testing as the diagnostic standard.

Nerve conduction studies and electromyography

Electrophysiology shows a nerve length-dependent sensorimotor neuropathy. Sensory nerve action potentials are characteristically very low or absent - their recovery was used as an objective outcome measure in the gene therapy trial.

Show evidence (2 references)

PMID:38507752 SUPPORT Human Clinical

"Peripheral axonal loss in giant axonal neuropathy causes progressive sensorimotor neuropathy, as indicated on electrophysiological testing and histologic analysis of the peripheral nerves."

Establishes electrophysiology and nerve histology as the modalities demonstrating the peripheral axonal loss.

PMID:38507752 SUPPORT Human Clinical

"Between 6 and 24 months after gene transfer, sensory-nerve action potential amplitudes increased, stopped declining, or became recordable after being absent in 6 participants but remained absent in 8."

Shows sensory nerve action potentials are absent or severely reduced at baseline in most patients, and usable as a quantitative diagnostic and outcome measure.

Brain MRI

T2-weighted hyperintensity in the periventricular regions and cerebellar white matter, sometimes described as a leukoencephalopathy or leukodystrophy - the radiological signature of the central arm of the disease.

Show evidence (1 reference)

PMID:39680150 SUPPORT Human Clinical

"Magnetic resonance imaging (MRI) shows high signals on T2-weighted sequences in the anterior and posterior periventricular regions as well as in the cerebellar white matter, sometimes referred to as leukoencephalopathy or leukodystrophy."

Describes the characteristic MRI findings used diagnostically.

📊

Prevalence

1

Worldwide

Cases In Literature Ultra Rare

Approximately 75 families reported worldwide. No defensible population prevalence or incidence rate, carrier frequency, or sex ratio has been established for this disease, so no rate_per_100000 is recorded.

Show evidence (1 reference)

PMID:39680150 SUPPORT Human Clinical

"Thus far, this neurological condition has been reported in approximately 75 families worldwide"

States the total number of ascertained families, which is the only defensible occurrence figure for this disease. Note this counts families, not individuals.

🔬

Clinical Trials

1

NCT02362438 PHASE_I COMPLETED

Intrathecal dose-escalation study of scAAV9/JeT-GAN in children with giant axonal neuropathy; safety was the primary end point, with change in the 32-item Motor Function Measure total percent score as key secondary clinical end point.

Show evidence (3 references)

PMID:38507752 SUPPORT Human Clinical

"We conducted an intrathecal dose-escalation study of scAAV9/JeT-GAN (a self-complementary adeno-associated virus-based gene therapy containing the GAN transgene) in children with giant axonal neuropathy. Safety was the primary end point."

Describes the trial design and primary end point.

PMID:38507752 SUPPORT Human Clinical

"Participants older than 6 years of age with genetically confirmed giant axonal neuropathy were enrolled from April 2015 through August 2020."

Records the enrollment window, which closed in August 2020.

clinicaltrials:NCT02362438 SUPPORT Other

"Participants will have a total of about 27 visits, weekly, monthly, and then yearly over 15 years."

The registry record's own long-term follow-up schedule.

🧫

Experimental Models

1

GAN patient dermal fibroblasts (vimentin aggregate assay) PRIMARY_CELL_CULTURE

Primary skin fibroblasts from GAN patients accumulate vimentin intermediate filament aggregates, providing an accessible non-neural readout of the generalized defect and the assay used to demonstrate rescue by GAN gene transfer.

Pathograph links

Intermediate Filament Aggregation recapitulates fidelity: high Patient-derived cells reproduce the defining cellular lesion in the patient's own genetic background.

Limitations: Fibroblasts report the vimentin arm of a generalized intermediate filament defect and cannot model the axonal geometry, giant axon formation, or the neuronal degeneration that determine the clinical phenotype.

Readouts

Proportion of cells displaying vimentin IF aggregates

Direction: RESTORED

Interpretation: Aggregate-bearing cell counts fall after delivery of a normal GAN transgene, tying the cellular phenotype to gigaxonin deficiency.

Show evidence (1 reference)

PMID:23316953 SUPPORT In Vitro

"Treatment of primary skin fibroblast cultures from three different GAN patients with an adeno-associated virus type 2 (AAV2) vector containing a normal human GAN transgene significantly reduced the number of cells displaying vimentin IF aggregates."

Reports the measurement and its direction after gene transfer.

Show evidence (1 reference)

PMID:23585478 SUPPORT In Vitro

"In GAN, aggregates of intermediate filaments (IFs) represent the main pathological feature detected in neurons and other cell types, including patients' dermal fibroblasts."

Establishes that patient fibroblasts carry the same defining lesion, which is what makes them informative for this node.

🐁

Animal Models

2

Gan knockout mouse

Gigaxonin-null mice accumulate neuronal intermediate filaments and show peripheral nerve pathology and rotarod deficits, and were the vehicle for preclinical intrathecal AAV9 gene-transfer studies.

Species

Mouse

Genotype

Gan-/-

Publication

PMID:29766026

Pathograph links

Intermediate Filament Aggregation partially recapitulates fidelity: low The knockout reproduces intermediate filament accumulation and peripheral nerve pathology, and these are reversible by GAN gene transfer, which is what made it usable for preclinical gene-transfer work.

Limitations: Downgraded from RECAPITULATES/MODERATE on the strength of PMID:41402936, which reports that the early knockout strains failed to reproduce the severity and histopathology of human disease: mild, late-onset (>12 months) symptoms with no overt degeneration and, critically, no giant axons and no neurofilament compaction - the defining human lesions. Phenotype also varies with genetic background. Inferences about the giant axon and CNS arms of the disease should use the A49E knock-in instead.

Readouts

Neuronal intermediate filament accumulation and sciatic nerve ultrastructure

Direction: RESTORED

Interpretation: Intrathecal gene transfer preserved nerve ultrastructure and reduced intermediate filament accumulation, linking the aggregation node to gigaxonin dose.

Show evidence (1 reference)

PMID:29766026 SUPPORT Model Organism

"IT delivery of AAV9/JeT-GAN in aged GAN KO mice preserved sciatic nerve ultrastructure, reduced neuronal IF accumulations and attenuated rotarod dysfunction."

Reports the measured structural and functional readouts in the knockout.

Show evidence (2 references)

PMID:41402936 SUPPORT Model Organism

"Indeed, the homozygous KO mice exhibit mild symptoms with late onset (> 12 months of age), no overt degeneration, absence of giant axons and compaction of NFs, which is seen in patients"

Directly limits what the knockout can support - it lacks the defining human lesions - which is why the relationship is PARTIALLY_RECAPITULATES rather than RECAPITULATES.

+ 1 more reference

GAN A49E knock-in mouse

A knock-in of a disease-causing GAN missense mutation rather than a gene deletion. Unlike the earlier knockout strains it produces an overt phenotype - early sensory-motor deficits and ataxia, giant axons, demyelination, and the neurofilament compaction and disorganization seen in patients - making it the first rodent model to reproduce the histological hallmarks. It also reveals neuromuscular junction and muscle involvement, and a sex bias with females more severely affected that has no established human counterpart.

Species

Mouse

Genotype

GAN A49E/A49E knock-in

Publication

PMID:41402936

Pathograph links

Giant Axon Formation recapitulates fidelity: high Reproduces the pathognomonic lesion - giant axons with compacted, disorganized neurofilaments - which the knockout strains do not.

Limitations: Carries one specific missense allele (A49E), so it models the dominant mechanism of gigaxonin protein instability rather than the full mutational spectrum. The female-biased severity has no established human counterpart.

Readouts

Giant axons and neurofilament compaction across the nervous system

Direction: INCREASED

Interpretation: Presence of the human histological hallmark, absent from prior knockout models, is what makes this strain informative for this node.

Show evidence (1 reference)

PMID:41402936 SUPPORT Model Organism

"GANA49E/A49E mice exhibit early sensory-motor deficits and ataxia, giant axons and demyelination which, together with increased abundance, dramatic compaction and disorganization of neurofilaments across the nervous system, mimics the human disease."

Reports the histological and behavioural readouts in this strain.

Show evidence (1 reference)

PMID:41402936 SUPPORT Model Organism

"Altogether, the GANA49E strain provides the first robust rodent model for GAN, recapitulating the symptoms and histological hallmarks of the human pathology."

The authors' own assessment that this strain recapitulates the disease, which is the basis for treating it as informative here.

{ }

Source YAML

click to show

name: Giant Axonal Neuropathy 1
creation_date: '2026-08-20T00:00:00Z'
category: Mendelian
synonyms:
- GAN
- GAN1
- giant axonal neuropathy 1
- giant axonal neuropathy type 1
- neuropathy, giant axonal
- giant axonal neuropathy caused by mutation in GAN
- GAN-related neurodegeneration
description: >-
  Giant axonal neuropathy 1 (GAN) is an ultra-rare, early-childhood-onset,
  autosomal recessive neurodegenerative disorder caused by biallelic
  loss-of-function variants in GAN (16q23.2), which encodes gigaxonin.
  Gigaxonin is a substrate-specific adaptor for a cullin-3 (CUL3) ubiquitin
  ligase complex and is the first identified factor controlling degradation of
  the entire intermediate filament family. Loss of functional gigaxonin
  therefore removes the rate-setting step in intermediate filament turnover,
  producing generalized accumulation and disorganized aggregation of
  tissue-specific intermediate filaments — neurofilaments and peripherin in
  neurons, vimentin in fibroblasts, Schwann cells and endothelium, GFAP in
  astrocytes, and keratins in hair. In axons this yields the pathognomonic
  focal swellings densely packed with disorganized intermediate filaments,
  the "giant axons" that name the disease.


  The disorder is best understood as a phenotypic continuum rather than a
  single stereotyped presentation. At the severe end, the classic phenotype
  begins in the first years of life as a prominent sensorimotor peripheral
  neuropathy and evolves to add central nervous system involvement —
  cerebellar signs, pyramidal signs, intellectual disability and seizures —
  with loss of independent ambulation in the second decade and death usually in
  the third decade, most often from pulmonary complications. At the milder end
  is a later-onset, slower-progressing phenotype largely restricted to the
  peripheral nervous system that overlaps clinically with axonal
  Charcot-Marie-Tooth disease. Both ends arise from the same mechanism of
  biallelic GAN loss of function. Dry, tightly curled hair unlike that of
  either parent is a characteristic clinical clue, reflecting the keratin arm
  of the same generalized intermediate filament defect.


  Because the defect is generalized rather than neuron-restricted, it is
  detectable in accessible non-neural tissue: patient dermal fibroblasts
  accumulate vimentin aggregates, which supports a cellular assay and provides
  the readout used in preclinical gene-transfer work. Intrathecal
  AAV9-mediated GAN gene transfer (scAAV9/JeT-GAN) has been evaluated in a
  first-in-human phase 1 dose-escalation trial.
disease_term:
  preferred_term: giant axonal neuropathy 1
  term:
    id: MONDO:0009749
    label: giant axonal neuropathy 1
parents:
- Hereditary peripheral neuropathy
- Axonal neuropathy
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0009749
      label: giant axonal neuropathy 1
    mapping_predicate: skos:exactMatch
    mapping_source: MONDO
  - term:
      id: MONDO:0000128
      label: giant axonal neuropathy
    mapping_predicate: skos:broadMatch
    mapping_source: MONDO
    notes: >-
      The OMIM phenotypic-series parent, spanning this entry's GAN/gigaxonin
      disease and the distinct DCAF8 disease giant axonal neuropathy 2
      (MONDO:0012411). Recorded as broadMatch, which per the mapping policy does
      not retire the parent concept from the curation queue - GAN2 remains
      uncurated.
references:
- reference: PMID:20301315
  title: GAN-Related Neurodegeneration.
  tags:
  - GeneReviews
inheritance:
- name: Autosomal recessive inheritance
  description: >-
    GAN-related neuropathy is inherited in an autosomal recessive manner; each
    sib of an affected individual has a 25% chance of inheriting biallelic
    pathogenic variants.
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  evidence:
  - reference: PMID:20301315
    reference_title: "GAN-Related Neurodegeneration."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "GAN-related neuropathy is inherited in an autosomal recessive manner."
    explanation: GeneReviews states the mode of inheritance directly.
has_subtypes:
- name: Classic GAN
  display_name: Classic giant axonal neuropathy (severe, PNS plus CNS)
  description: >-
    The severe end of the continuum. Infantile-onset severe peripheral motor
    and sensory neuropathy evolving into central nervous system impairment
    (intellectual disability, seizures, cerebellar signs and pyramidal tract
    signs), with wheelchair dependence in the second decade and death usually
    in the third decade.
  evidence:
  - reference: PMID:20301315
    reference_title: "GAN-Related Neurodegeneration."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The classic giant axonal neuropathy phenotype typically manifests
      as an infantile-onset neurodegenerative disorder, starting as a severe
      peripheral motor and sensory neuropathy and evolving into central nervous
      system impairment (intellectual disability, seizures, cerebellar signs,
      and pyramidal tract signs)."
    explanation: GeneReviews defines the classic severe phenotype at this end of
      the continuum.
  - reference: PMID:39680150
    reference_title: "Giant axonal neuropathy (GAN): cross-sectional data on phenotypes, genotypes, and proteomic signature from a German cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "From the 15 patients described here, 13 (86.7%) had a classical and
      one a mild CMT-like phenotype."
    explanation: Quantifies the predominance of the classic phenotype over the
      CMT-like phenotype in a systematically ascertained cohort.
- name: CMT-like GAN
  display_name: Milder CMT-like giant axonal neuropathy (predominantly peripheral)
  description: >-
    The mild end of the continuum: predominantly motor and sensory neuropathy
    with little to no CNS involvement, overlapping clinically with the axonal
    forms of Charcot-Marie-Tooth neuropathy, and later-onset and
    slower-progressing than the classic phenotype. Identified as a distinct
    subcohort in the largest reported natural history cohort. Same genetic
    mechanism as classic GAN — biallelic GAN loss of function — so this is a
    phenotypic, not a mechanistic, division.
  evidence:
  - reference: PMID:20301315
    reference_title: "GAN-Related Neurodegeneration."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "At the milder end of the spectrum are predominantly motor and
      sensory neuropathies (with little to no CNS involvement) that overlap with
      the axonal form of Charcot-Marie-Tooth neuropathies."
    explanation: GeneReviews defines the mild end of the phenotypic continuum.
  - reference: PMID:34114613
    reference_title: "Giant axonal neuropathy: cross-sectional analysis of a large natural history cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Importantly, we identified and characterized a subcohort of
      individuals with a milder form of GAN and with a presentation similar to
      Charcot-Marie-Tooth disease."
    explanation: The natural history cohort independently identifies and
      characterizes this subcohort as distinct from the classic presentation.
pathophysiology:
- name: Gigaxonin Loss of Function
  biological_scale: MOLECULAR
  description: >-
    Biallelic loss-of-function variants in GAN (16q23.2) abolish functional
    gigaxonin, the substrate-specific adaptor that recruits intermediate
    filament proteins to a cullin-3 ubiquitin ligase complex. Gigaxonin is a
    ubiquitously expressed, low-abundance protein composed of an N-terminal BTB
    domain followed by six kelch repeats.
  molecular_functions:
  - preferred_term: gigaxonin substrate-adaptor activity in a cullin-3 ubiquitin ligase complex
    modifier: LOSS_OF_FUNCTION
    term:
      id: GO:0031625
      label: ubiquitin protein ligase binding
  downstream:
  - target: Impaired Intermediate Filament Degradation
    causal_link_type: DIRECT
  - target: Intermediate Filament Transport Failure
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:37043392
      reference_title: "Gigaxonin is required for intermediate filament transport."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "We have demonstrated that the loss of gigaxonin dramatically
        inhibited transport of IFs along microtubules by the microtubule motor
        kinesin-1."
      explanation: States the edge directly - loss of gigaxonin inhibits
        intermediate filament transport.
  evidence:
  - reference: PMID:11062483
    reference_title: "The gene encoding gigaxonin, a new member of the cytoskeletal BTB/kelch repeat family, is mutated in giant axonal neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Gigaxonin is composed of an amino-terminal BTB (for Broad-Complex,
      Tramtrack and Bric a brac) domain followed by a six kelch repeats, which
      are predicted to adopt a beta-propeller shape."
    explanation: The gene-discovery paper establishes the domain architecture of
      gigaxonin that underlies its adaptor role.
  - reference: PMID:34114613
    reference_title: "Giant axonal neuropathy: cross-sectional analysis of a large natural history cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The disease is caused by biallelic mutations in the GAN gene
      located on 16q23.2, leading to loss of functional gigaxonin, a substrate
      specific ubiquitin ligase adapter protein necessary for the regulation of
      intermediate filament turnover."
    explanation: States the causal genetic lesion, its locus, and the molecular
      role of the lost protein.
- name: Impaired Intermediate Filament Degradation
  biological_scale: MOLECULAR
  description: >-
    Without gigaxonin-directed ubiquitination, intermediate filament proteins
    escape proteasomal turnover. Gigaxonin controls degradation of the entire
    intermediate filament family — vimentin in fibroblasts, and peripherin and
    neurofilament proteins in neurons — and proteasome inhibition reverses the
    clearance produced by gigaxonin overexpression, placing the defect in the
    ubiquitin-proteasome pathway.
  biological_processes:
  - preferred_term: proteasomal degradation of intermediate filament proteins
    modifier: DECREASED
    term:
      id: GO:0043161
      label: proteasome-mediated ubiquitin-dependent protein catabolic process
  - preferred_term: protein polyubiquitination of intermediate filament substrates
    modifier: DECREASED
    term:
      id: GO:0000209
      label: protein polyubiquitination
  downstream:
  - target: Intermediate Filament Aggregation
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:23585478
    reference_title: "Giant axonal neuropathy-associated gigaxonin mutations impair intermediate filament protein degradation."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Gigaxonin was similarly involved in the degradation of peripherin
      and neurofilament IF proteins in neurons."
    explanation: The cell-based arm - gigaxonin-dependent degradation of the
      neuronal intermediate filament substrates.
  - reference: PMID:23585478
    reference_title: "Giant axonal neuropathy-associated gigaxonin mutations impair intermediate filament protein degradation."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Using fibroblasts from patients and normal individuals, as well as
      Gan-/- mice, we demonstrated that gigaxonin was responsible for the
      degradation of vimentin IFs."
    explanation: The same finding established in the Gan-knockout mouse. Split
      from the in vitro item above so each evidence item carries a single
      evidence_source, per the mixed-source rule.
  - reference: PMID:23585478
    reference_title: "Giant axonal neuropathy-associated gigaxonin mutations impair intermediate filament protein degradation."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Furthermore, proteasome inhibition by MG-132 reversed the clearance
      of IF proteins in cells overexpressing gigaxonin, demonstrating the
      involvement of the proteasomal degradation pathway."
    explanation: Establishes that the degradation route is proteasomal, which is
      what makes loss of the adaptor sufficient to cause accumulation.
  - reference: PMID:26778561
    reference_title: "Degradation of the Intermediate Filament Family by Gigaxonin."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Here, we will focus on the first identified factor controlling the
      degradation of the entire intermediate filament family, the gigaxonin-E3
      ligase."
    explanation: Review establishing that gigaxonin controls the whole
      intermediate filament family, not one filament type.
  - reference: PMID:37903270
    reference_title: "The CRL3(gigaxonin) ubiquitin ligase-USP15 pathway governs the destruction of neurofilament proteins."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Here, we report that the CRL3GIG-USP15 pathway governs the
      destruction of NF proteins NEFL and INA."
    explanation: Identifies the specific neurofilament substrates and the
      CUL3-RBX1-gigaxonin ligase complex acting on them.
  - reference: PMID:37903270
    reference_title: "The CRL3(gigaxonin) ubiquitin ligase-USP15 pathway governs the destruction of neurofilament proteins."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Notably, mutations in the C-terminal Kelch domain of GIG,
      represented by L309R, R545C, and C570Y, disrupted the binding of GIG to
      NEFL and INA, leading to the accumulation of these NF proteins. This
      accounts for the loss-of-function mutations in GAN patients."
    explanation: Connects specific patient Kelch-domain variants to failed
      substrate binding, which is the molecular basis of the degradation defect.
- name: Intermediate Filament Transport Failure
  biological_scale: CELLULAR
  description: >-
    Beyond failed degradation, loss of gigaxonin dramatically inhibits
    kinesin-1-driven transport of intermediate filaments along microtubules.
    The defect is selective — other kinesin-1 cargoes apart from mitochondria
    move normally — and forcing kinesin-1 to bind filaments directly rescues
    their distribution, which places transport failure upstream of the abnormal
    distribution rather than downstream of it. A more than 20-fold rise in
    soluble vimentin oligomers accompanies the block.
  biological_processes:
  - preferred_term: kinesin-1-driven microtubule-based transport of intermediate filaments
    modifier: DECREASED
    term:
      id: GO:0099111
      label: microtubule-based transport
  downstream:
  - target: Intermediate Filament Aggregation
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:37043392
    reference_title: "Gigaxonin is required for intermediate filament transport."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "We have demonstrated that the loss of gigaxonin dramatically
      inhibited transport of IFs along microtubules by the microtubule motor
      kinesin-1. This inhibition was specific for IFs, as other kinesin-1
      cargoes, with the exception of mitochondria, were transported normally."
    explanation: Establishes the transport defect and its selectivity for
      intermediate filaments.
  - reference: PMID:37043392
    reference_title: "Gigaxonin is required for intermediate filament transport."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Abnormal distribution of IFs in the cytoplasm can be rescued by
      direct binding of kinesin-1 to IFs, demonstrating that transport
      inhibition is the primary cause for the abnormal IF distribution."
    explanation: The rescue experiment is what makes transport failure causal
      rather than a secondary consequence of aggregation.
  notes: >-
    Curated as a parallel arm to failed degradation rather than a consequence of
    it. The authors' own proposed mechanism is that excess soluble vimentin
    oligomers saturate an unidentified kinesin-1 adapter, which would make this
    arm downstream of the degradation defect; that linkage is explicitly
    speculative in the source and is not asserted here.
- name: Intermediate Filament Aggregation
  biological_scale: CELLULAR
  description: >-
    Undegraded intermediate filaments accumulate as disorganized aggregates.
    Because gigaxonin is ubiquitously expressed, the aggregation is generalized
    and tissue-specific: vimentin in endothelial cells, Schwann cells and
    cultured skin fibroblasts, GFAP in astrocytes, neurofilaments and peripherin
    in neurons, and — the likely basis of the hair phenotype — keratins.
  cell_types:
  - preferred_term: dermal fibroblast
    term:
      id: CL:0000057
      label: fibroblast
  - preferred_term: astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  - preferred_term: sensory neuron of dorsal root ganglion
    term:
      id: CL:1001451
      label: sensory neuron of dorsal root ganglion
  biological_processes:
  - preferred_term: disorganization of the intermediate filament cytoskeleton
    modifier: ABNORMAL
    term:
      id: GO:0045104
      label: intermediate filament cytoskeleton organization
  - preferred_term: intermediate filament inclusion body formation
    modifier: INCREASED
    term:
      id: GO:0070841
      label: inclusion body assembly
  downstream:
  - target: Giant Axon Formation
    causal_link_type: DIRECT
  - target: Central Nervous System Degeneration
    causal_link_type: DIRECT
  - target: Autophagy-Lysosome Failure
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:11062483
    reference_title: "The gene encoding gigaxonin, a new member of the cytoskeletal BTB/kelch repeat family, is mutated in giant axonal neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "GAN corresponds to a generalized disorganization of the
      cytoskeletal intermediate filaments (IFs), to which neurofilaments belong,
      as abnormal aggregation of multiple tissue-specific IFs has been reported:
      vimentin in endothelial cells, Schwann cells and cultured skin
      fibroblasts, and glial fibrillary acidic protein (GFAP) in astrocytes."
    explanation: Establishes that the aggregation is generalized across cell
      types rather than restricted to neurons.
  - reference: PMID:23585478
    reference_title: "Giant axonal neuropathy-associated gigaxonin mutations impair intermediate filament protein degradation."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "In GAN, aggregates of intermediate filaments (IFs) represent the
      main pathological feature detected in neurons and other cell types,
      including patients' dermal fibroblasts."
    explanation: Identifies intermediate filament aggregates as the principal
      cellular lesion, including in accessible patient fibroblasts.
- name: Autophagy-Lysosome Failure
  biological_scale: CELLULAR
  description: >-
    A secondary, feed-forward consequence of the accumulation rather than a
    parallel cause of it. Neurofilament accumulations disrupt autophagy by two
    distinct routes: they interfere with the distribution of autophagic
    organelles, impairing maturation and fusion with lysosomes; and they
    sequester the chaperone 14-3-3, which is required for correct localization
    of the master autophagy regulator TFEB. Because degradative capacity is
    itself degraded, the arm feeds back onto the accumulation that produced it.
  biological_processes:
  - preferred_term: autophagosome-lysosome fusion
    modifier: DECREASED
    term:
      id: GO:0061909
      label: autophagosome-lysosome fusion
  downstream:
  - target: Intermediate Filament Aggregation
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      The feed-forward limb: loss of autophagic-lysosomal degradative capacity
      compounds the accumulation that caused it. Curated as indirect because the
      source demonstrates the autophagy defect and proposes its contribution to
      pathogenesis rather than measuring the return effect on filament load.
  evidence:
  - reference: PMID:40059823
    reference_title: "Neurofilament accumulation disrupts autophagy in giant axonal neuropathy."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Using a combination of genetic and RNA interference approaches, we
      found that dorsal root ganglia from mice lacking gigaxonin have impaired
      autophagy and lysosomal degradation through 2 mechanisms."
    explanation: Establishes the autophagy-lysosome defect in gigaxonin-null
      dorsal root ganglia and that it operates by two mechanisms.
  - reference: PMID:40059823
    reference_title: "Neurofilament accumulation disrupts autophagy in giant axonal neuropathy."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "First, neurofilament accumulations interfere with the distribution
      of autophagic organelles, impairing their maturation and fusion with
      lysosomes. Second, the accumulations attract the chaperone 14-3-3, which
      is responsible for the proper localization of the key autophagy regulator
      transcription factor EB (TFEB)."
    explanation: Names both routes and, critically, their direction - the
      accumulations act on autophagy, not the reverse.
  notes: >-
    Direction matters here and is easy to invert: this is neurofilament
    accumulation causing autophagy failure, not a primary autophagy defect
    causing accumulation. The entry does not conform this node to
    loss_of_proteostasis#Misfolded-Protein Aggregation, because GAN aggregation
    is failure of regulated degradation of correctly folded intermediate
    filaments rather than misfolding.
- name: Giant Axon Formation
  biological_scale: CELLULAR
  description: >-
    In axons the accumulating intermediate filaments produce the pathognomonic
    focal swellings — segmental distension of the axon densely packed with
    disorganized neurofilaments — that give the disease its name.
  biological_processes:
  - preferred_term: neurofilament cytoskeleton organization
    modifier: ABNORMAL
    term:
      id: GO:0060052
      label: neurofilament cytoskeleton organization
  downstream:
  - target: Distal Axonal Degeneration
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Curated as indirect with unknown intermediates rather than DIRECT: giant
      axons and axonal loss both follow intermediate filament accumulation, and
      whether the swellings themselves cause the degeneration or are a parallel
      manifestation of the same underlying accumulation is not established.
  evidence:
  - reference: PMID:11062483
    reference_title: "The gene encoding gigaxonin, a new member of the cytoskeletal BTB/kelch repeat family, is mutated in giant axonal neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Giant axonal neuropathy (GAN, MIM 256850), a severe, autosomal
      recessive sensorimotor neuropathy affecting both the peripheral nerves and
      the central nervous system, is characterized by neurofilament
      accumulation, leading to segmental distension of the axons."
    explanation: Describes the defining axonal lesion and its neurofilament
      basis.
  - reference: PMID:29766026
    reference_title: "Development of Intrathecal AAV9 Gene Therapy for Giant Axonal Neuropathy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The pathologic signature of GAN is giant axonal swellings filled
      with disorganized accumulations of IFs."
    explanation: States the pathognomonic finding explicitly.
- name: Central Nervous System Degeneration
  biological_scale: TISSUE
  description: >-
    The central arm of the disease, parallel to peripheral axonal degeneration
    rather than downstream of it. Intermediate filament aggregation in central
    neurons and in astrocytes (where GFAP is the accumulating filament) is
    accompanied by inclusion bodies in brain, neuroinflammation, and loss of
    cortical and spinal neurons, and appears radiologically as periventricular
    and cerebellar white-matter T2 hyperintensity. This is the route by which
    cerebellar signs, pyramidal signs and cognitive decline arise; they are not
    consequences of distal peripheral axon loss.
  cell_types:
  - preferred_term: astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  biological_processes:
  - preferred_term: neuronal apoptosis in cortex and spinal cord
    modifier: INCREASED
    term:
      id: GO:0051402
      label: neuron apoptotic process
  downstream:
  - target: Progressive Neurological Decline
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:34114613
    reference_title: "Giant axonal neuropathy: cross-sectional analysis of a large natural history cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "presents as a prominent sensorimotor neuropathy and commonly
      progresses to affect both the PNS and CNS"
    explanation: Establishes in a human cohort that central nervous system
      involvement is a distinct feature of the disease course, not merely a
      description of the peripheral neuropathy.
  - reference: PMID:39680150
    reference_title: "Giant axonal neuropathy (GAN): cross-sectional data on phenotypes, genotypes, and proteomic signature from a German cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Magnetic resonance imaging (MRI) shows high signals on T2-weighted
      sequences in the anterior and posterior periventricular regions as well as
      in the cerebellar white matter, sometimes referred to as
      leukoencephalopathy or leukodystrophy."
    explanation: The radiological correlate of central white-matter involvement
      in human patients.
  - reference: PMID:37137704
    reference_title: "A New Mouse Model of Giant Axonal Neuropathy with Overt Phenotypes and Neurodegeneration Driven by Neurofilament Disorganization."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Abundant inclusion bodies composed of disorganized IFs were also
      detected in the brain of Gan-/-;TgPer mice."
    explanation: Shows central intermediate filament inclusion pathology in
      brain, the mechanistic link between the aggregation node and CNS disease.
  - reference: PMID:37137704
    reference_title: "A New Mouse Model of Giant Axonal Neuropathy with Overt Phenotypes and Neurodegeneration Driven by Neurofilament Disorganization."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "The disease was associated with neuroinflammation and substantial
      loss of cortical neurons and spinal neurons."
    explanation: Reports the neuroinflammation and central neuronal loss this
      node asserts.
  notes: >-
    How much of the central disease is attributable to intermediate filament
    disorganization specifically is not settled - the model-organism source
    states only that IF disorganization "can drive some neurodegenerative
    changes", and gigaxonin has substrates beyond intermediate filaments. The
    edge is curated as DIRECT on the strength of the human CNS involvement and
    the brain inclusion pathology, not as a claim that IF aggregation is the
    sole cause.
- name: Distal Axonal Degeneration
  biological_scale: CELLULAR
  conforms_to: "peripheral_axonal_degeneration#Distal Axonal Degeneration and Demyelination"
  description: >-
    Peripheral axonal loss follows, producing the progressive, nerve
    length-dependent sensorimotor neuropathy that dominates early disease. This
    is the final common pathway shared with other axonal neuropathies; in GAN
    the upstream driver is intermediate filament aggregation rather than a
    primary transport or myelin lesion.
  downstream:
  - target: Progressive Neurological Decline
    causal_link_type: DIRECT
  cell_types:
  - preferred_term: myelinating Schwann cell
    term:
      id: CL:0000218
      label: myelinating Schwann cell
  biological_processes:
  - preferred_term: axon ensheathment by myelinating Schwann cells
    modifier: DECREASED
    term:
      id: GO:0008366
      label: axon ensheathment
  - preferred_term: neuronal apoptosis following axonal loss
    modifier: INCREASED
    term:
      id: GO:0051402
      label: neuron apoptotic process
  evidence:
  - reference: PMID:38507752
    reference_title: "Intrathecal Gene Therapy for Giant Axonal Neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Peripheral axonal loss in giant axonal neuropathy causes
      progressive sensorimotor neuropathy, as indicated on electrophysiological
      testing and histologic analysis of the peripheral nerves."
    explanation: States the axonal-loss-to-neuropathy step this node asserts,
      with the electrophysiological and histological basis for it.
  - reference: PMID:23316953
    reference_title: "Restoration of cytoskeleton homeostasis after gigaxonin gene transfer for giant axonal neuropathy."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "On a cellular level GAN is characterized by intermediate filament
      (IF) aggregation, leading to a progressive and fatal peripheral neuropathy
      in humans."
    explanation: Links the cellular aggregation lesion to the progressive
      peripheral neuropathy. Tagged IN_VITRO because the paper reports patient
      fibroblast and Gan-knockout mouse experiments, not human clinical data;
      this sentence is its framing of the disease.
- name: Progressive Neurological Decline
  biological_scale: ORGANISM
  description: >-
    Peripheral neuropathy is joined over time by central nervous system
    degeneration, giving the polysymptomatic course: cerebellar dysfunction,
    pyramidal signs, cognitive decline, vision loss, loss of ambulation, and
    death from pulmonary complications, typically in the third decade.
  evidence:
  - reference: PMID:34114613
    reference_title: "Giant axonal neuropathy: cross-sectional analysis of a large natural history cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Giant axonal neuropathy (GAN) is an ultra-rare autosomal
      recessive, progressive neurodegenerative disease with early childhood
      onset that presents as a prominent sensorimotor neuropathy and commonly
      progresses to affect both the PNS and CNS."
    explanation: Describes the characteristic progression from peripheral to
      combined peripheral and central involvement.
  - reference: PMID:20301315
    reference_title: "GAN-Related Neurodegeneration."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Most affected individuals become wheelchair dependent in the second
      decade of life and eventually bedridden with severe polyneuropathy,
      ataxia, and dementia. Death usually occurs in the third decade."
    explanation: GeneReviews states the functional trajectory and life
      expectancy.
phenotypes:
- category: Neurologic
  name: Peripheral sensorimotor axonal neuropathy
  description: >-
    The presenting and dominant feature: a progressive, nerve length-dependent
    sensorimotor neuropathy beginning in early childhood.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Peripheral axonal neuropathy
    term:
      id: HP:0003477
      label: Peripheral axonal neuropathy
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:34114613
    reference_title: "Giant axonal neuropathy: cross-sectional analysis of a large natural history cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Giant axonal neuropathy (GAN) is an ultra-rare autosomal
      recessive, progressive neurodegenerative disease with early childhood
      onset that presents as a prominent sensorimotor neuropathy and commonly
      progresses to affect both the PNS and CNS."
    explanation: >-
      The natural history cohort describes the sensorimotor neuropathy as the
      presenting feature of the disease. Note this sentence carries no
      denominator - the VERY_FREQUENT band is a mapping of "presents as a
      prominent sensorimotor neuropathy" as a defining feature, corroborated by
      the German cohort's muscle weakness 15/15 and abnormal reflexes 12/15
      rows, not a figure quoted from this source.
- category: Integumentary
  name: Tightly curled kinky hair
  description: >-
    Dry, tightly curled hair unlike that of either parent — a characteristic
    early clinical clue, attributed to involvement of keratin intermediate
    filaments by the same generalized mechanism.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Curly hair
    term:
      id: HP:0002212
      label: Curly hair
  evidence:
  - reference: PMID:11062483
    reference_title: "The gene encoding gigaxonin, a new member of the cytoskeletal BTB/kelch repeat family, is mutated in giant axonal neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Keratin IFs also seem to be alterated, as most patients present
      characteristic curly or kinky hairs."
    explanation: Reports the hair phenotype and attributes it to the keratin arm
      of the intermediate filament defect.
  - reference: PMID:39680150
    reference_title: "Giant axonal neuropathy (GAN): cross-sectional data on phenotypes, genotypes, and proteomic signature from a German cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Phenotypic abnormality8 (53.3) Curly/Frizzy hair14 (93.3) Abnormal skull morphology2 (13.3)"
    explanation: HPO-coded frequency row from the German cohort (14 of 15
      patients), supporting the VERY_FREQUENT band.
  - reference: ORPHA:643
    reference_title: "Giant axonal neuropathy"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "characteristic kinky hair in most cases"
    explanation: Orphanet's own definition independently corroborates the hair
      phenotype as characteristic and present in most patients, agreeing with
      the German cohort's 93.3% and with the VERY_FREQUENT band.
- category: Neurologic
  name: Sensory ataxia
  description: >-
    Sensory ataxia appears in the first few years of life alongside the hair
    phenotype.
  phenotype_term:
    preferred_term: Sensory ataxia
    term:
      id: HP:0010871
      label: Sensory ataxia
  evidence:
  - reference: PMID:38507752
    reference_title: "Intrathecal Gene Therapy for Giant Axonal Neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Giant axonal neuropathy typically manifests with additional
      features of dry, tightly curled hair and sensory ataxia in the first few
      years of life."
    explanation: States the early presence of sensory ataxia.
- category: Neurologic
  name: Cerebellar dysfunction
  description: >-
    Cerebellar signs emerge as central nervous system involvement accrues.
  phenotype_term:
    preferred_term: Progressive cerebellar ataxia
    term:
      id: HP:0002073
      label: Progressive cerebellar ataxia
    clinical_course: PROGRESSIVE
  subtype: Classic GAN
  evidence:
  - reference: PMID:20301315
    reference_title: "GAN-Related Neurodegeneration."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "evolving into central nervous system impairment (intellectual
      disability, seizures, cerebellar signs, and pyramidal tract signs)"
    explanation: GeneReviews lists cerebellar signs among the CNS features of the
      classic phenotype.
- category: Neurologic
  name: Intellectual disability
  description: >-
    Cognitive impairment develops as part of the central nervous system
    involvement in the classic phenotype, progressing to dementia in advanced
    disease.
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  frequency: OCCASIONAL
  subtype: Classic GAN
  evidence:
  - reference: PMID:20301315
    reference_title: "GAN-Related Neurodegeneration."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "evolving into central nervous system impairment (intellectual
      disability, seizures, cerebellar signs, and pyramidal tract signs)"
    explanation: GeneReviews lists intellectual disability as a CNS feature of
      the classic phenotype.
  - reference: PMID:39680150
    reference_title: "Giant axonal neuropathy (GAN): cross-sectional data on phenotypes, genotypes, and proteomic signature from a German cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Intellectual disability4 (26.7)Gait Gait disturbance15 (100.0) Gait ataxia5 (33.3)"
    explanation: HPO-coded frequency row from the German cohort (4 of 15),
      supporting the OCCASIONAL band and showing that cognitive involvement is
      not universal even in a predominantly classic-phenotype cohort.
- category: Neurologic
  name: Seizures
  description: >-
    Seizures occur as part of the central nervous system involvement in the
    classic phenotype.
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  frequency: OCCASIONAL
  subtype: Classic GAN
  evidence:
  - reference: PMID:20301315
    reference_title: "GAN-Related Neurodegeneration."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "evolving into central nervous system impairment (intellectual
      disability, seizures, cerebellar signs, and pyramidal tract signs)"
    explanation: GeneReviews lists seizures as a CNS feature of the classic
      phenotype.
  - reference: PMID:39680150
    reference_title: "Giant axonal neuropathy (GAN): cross-sectional data on phenotypes, genotypes, and proteomic signature from a German cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Truncal ataxia3 (20.0) Seizures2 (13.3) Abnormality of the eye9 (60.0)"
    explanation: HPO-coded frequency row from the German cohort (2 of 15),
      supporting the OCCASIONAL band.
- category: Ophthalmologic
  name: Vision loss
  description: >-
    Vision loss is part of the polysymptomatic disease course.
  phenotype_term:
    preferred_term: Visual loss
    term:
      id: HP:0000572
      label: Visual loss
  evidence:
  - reference: PMID:38507752
    reference_title: "Intrathecal Gene Therapy for Giant Axonal Neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The disease course includes progressive, nerve length-dependent,
      sensorimotor neuropathy; cerebellar dysfunction; loss of unassisted
      independent ambulation by 8 to 10 years of age; vision loss; and secondary
      systemic complications."
    explanation: >-
      Lists vision loss among the features of the disease course. Bound to
      HP:0000572 Visual loss, which is exactly what the source states; the
      underlying ocular lesion is not specified by this evidence, so no more
      specific term (e.g. optic atrophy) is asserted.
- category: Neurologic
  name: Gait disturbance
  description: >-
    Abnormal gait is the presenting complaint, noted at a median age of 2 years
    and reported in every patient in the systematically ascertained German
    cohort.
  frequency: OBLIGATE
  phenotype_term:
    preferred_term: Gait disturbance
    term:
      id: HP:0001288
      label: Gait disturbance
  evidence:
  - reference: PMID:39680150
    reference_title: "Giant axonal neuropathy (GAN): cross-sectional data on phenotypes, genotypes, and proteomic signature from a German cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Abnormal gait was mentioned in all patients as one of the first
      symptoms, muscle weakness was notable in 13 (86.7%) patients"
    explanation: Reports gait abnormality in 15 of 15 patients as a presenting
      symptom. 15/15 maps to OBLIGATE; the cohort is small (n=15), so this is an
      obligate finding within the largest systematically ascertained series
      rather than a claim of 100% penetrance across all patients ever reported.
- category: Neurologic
  name: Distal muscle weakness
  description: >-
    Weakness is distal before proximal, in keeping with a length-dependent
    axonal neuropathy.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Distal muscle weakness
    term:
      id: HP:0002460
      label: Distal muscle weakness
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:39680150
    reference_title: "Giant axonal neuropathy (GAN): cross-sectional data on phenotypes, genotypes, and proteomic signature from a German cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Axial muscle weakness6 (40.0)  Distal muscle weakness12 (80.0)  Fatigable weakness5 (33.3)"
    explanation: HPO-coded frequency row from the German cohort (12 of 15),
      supporting the VERY_FREQUENT band.
- category: Neurologic
  name: Hypotonia
  description: Muscular hypotonia accompanies the neuropathy in most patients.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Hypotonia
    term:
      id: HP:0001252
      label: Hypotonia
  evidence:
  - reference: PMID:39680150
    reference_title: "Giant axonal neuropathy (GAN): cross-sectional data on phenotypes, genotypes, and proteomic signature from a German cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Muscular hypotonia14 (93.3) Abnormality of muscle size12 (80.0)"
    explanation: >-
      HPO-coded frequency row from the German cohort (14 of 15), supporting the
      VERY_FREQUENT band. Note the same paper's running text reports muscle
      hypotonia in 7 of 15 (46.7%) as a first symptom; the 93.3% figure quoted
      here is the cohort-wide HPO-coded row from Table 2. The two numbers
      describe onset versus ever-present and are not a discrepancy.
- category: Neurologic
  name: Areflexia
  description: >-
    Loss of deep tendon reflexes, the expected consequence of a severe
    length-dependent sensorimotor axonal neuropathy.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Areflexia
    term:
      id: HP:0001284
      label: Areflexia
  evidence:
  - reference: PMID:39680150
    reference_title: "Giant axonal neuropathy (GAN): cross-sectional data on phenotypes, genotypes, and proteomic signature from a German cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Abnormal reflexes12 (80.0)  Areflexia11 (73.3) Pyramidal sign2 (13.3)"
    explanation: HPO-coded frequency row from the German cohort (11 of 15),
      supporting the FREQUENT band.
- category: Musculoskeletal
  name: Limb joint contractures
  description: Contractures develop secondary to weakness and reduced mobility.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Limb joint contracture
    term:
      id: HP:0003121
      label: Limb joint contracture
  evidence:
  - reference: PMID:39680150
    reference_title: "Giant axonal neuropathy (GAN): cross-sectional data on phenotypes, genotypes, and proteomic signature from a German cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Limb joint contracture8 (53.3)  Ankle flexion contracture7 (46.7)"
    explanation: HPO-coded frequency row from the German cohort (8 of 15),
      supporting the FREQUENT band.
- category: Musculoskeletal
  name: Scoliosis
  description: Spinal deformity accompanying axial weakness and immobility.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Scoliosis
    term:
      id: HP:0002650
      label: Scoliosis
  evidence:
  - reference: PMID:39680150
    reference_title: "Giant axonal neuropathy (GAN): cross-sectional data on phenotypes, genotypes, and proteomic signature from a German cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Bone Scoliosis7 (46.7) Abnormality of joint mobility8 (53.3)"
    explanation: HPO-coded frequency row from the German cohort (7 of 15),
      supporting the FREQUENT band.
- category: Ophthalmologic
  name: Nystagmus
  description: Ocular involvement, part of the broader CNS disease.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Nystagmus
    term:
      id: HP:0000639
      label: Nystagmus
  evidence:
  - reference: PMID:39680150
    reference_title: "Giant axonal neuropathy (GAN): cross-sectional data on phenotypes, genotypes, and proteomic signature from a German cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Abnormality of the eye9 (60.0)  Nystagmus6 (40.0)"
    explanation: HPO-coded frequency row from the German cohort (6 of 15),
      supporting the FREQUENT band.
- category: Respiratory
  name: Respiratory insufficiency requiring ventilatory support
  description: >-
    Respiratory neuromuscular decline drives the pulmonary complications that
    are the usual cause of death.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Respiratory failure requiring assisted ventilation
    term:
      id: HP:0004887
      label: Respiratory failure requiring assisted ventilation
  evidence:
  - reference: PMID:39680150
    reference_title: "Giant axonal neuropathy (GAN): cross-sectional data on phenotypes, genotypes, and proteomic signature from a German cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Sleep apnoea3 (20.0) Need for ventilatory support2 (13.3)"
    explanation: HPO-coded frequency row from the German cohort (2 of 15). The
      band reflects need for ventilatory support at the cross-sectional visit in
      a cohort of average age 11.7 years, not lifetime risk, which is higher.
- category: Neurologic
  name: Muscle weakness
  description: >-
    Generalized muscle weakness, present in every patient in the German cohort
    and one of the two universal presenting features alongside gait disturbance.
  frequency: OBLIGATE
  phenotype_term:
    preferred_term: Muscle weakness
    term:
      id: HP:0001324
      label: Muscle weakness
  evidence:
  - reference: PMID:39680150
    reference_title: "Giant axonal neuropathy (GAN): cross-sectional data on phenotypes, genotypes, and proteomic signature from a German cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Muscle Muscle weakness15 (100.0)  Generalised muscle weakness5 (33.3)"
    explanation: HPO-coded frequency row from the German cohort (15 of 15). As with gait
      disturbance, 15/15 maps to OBLIGATE within this series rather than being a
      penetrance claim over all reported patients.
- category: Neurologic
  name: Skeletal muscle atrophy
  description: >-
    Amyotrophy accompanying denervation, distal more than proximal - a defining
    feature of the established neuropathy.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Skeletal muscle atrophy
    term:
      id: HP:0003202
      label: Skeletal muscle atrophy
  evidence:
  - reference: PMID:39680150
    reference_title: "Giant axonal neuropathy (GAN): cross-sectional data on phenotypes, genotypes, and proteomic signature from a German cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Abnormality of muscle size12 (80.0)  Generalised amyotrophy7 (46.07)"
    explanation: HPO-coded frequency row from the German cohort. The band is taken from
      the directly matching "Generalised amyotrophy" row (7 of 15, 46.07%), which
      supports FREQUENT. The broader "Abnormality of muscle size" row (12 of 15)
      is not specific to atrophy and so is not used to set the band.
- category: Neurologic
  name: Frequent falls
  description: >-
    An early functional consequence of the gait disturbance and weakness.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Frequent falls
    term:
      id: HP:0002359
      label: Frequent falls
  evidence:
  - reference: PMID:39680150
    reference_title: "Giant axonal neuropathy (GAN): cross-sectional data on phenotypes, genotypes, and proteomic signature from a German cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Frequent falls10 (66.7) Steppage gait6 (40.0)"
    explanation: HPO-coded frequency row from the German cohort (10 of 15), supporting the
      FREQUENT band.
- category: Neurologic
  name: Autonomic dysfunction
  description: >-
    Autonomic involvement, including bladder dysfunction. The first systematic
    clinical analysis of autonomic impairment in GAN was performed on a subset
    of the natural history cohort.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Abnormal autonomic nervous system physiology
    term:
      id: HP:0012332
      label: Abnormal autonomic nervous system physiology
  evidence:
  - reference: PMID:39680150
    reference_title: "Giant axonal neuropathy (GAN): cross-sectional data on phenotypes, genotypes, and proteomic signature from a German cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Abnormal autonomic nervous system physiology7 (46.7) Abnormal digestive system physiology6 (40.0)"
    explanation: HPO-coded frequency row from the German cohort (7 of 15), supporting the
      FREQUENT band.
- category: Musculoskeletal
  name: Abnormal foot morphology
  description: >-
    Foot deformity including pes planus, talipes and pes cavus, secondary to
    the length-dependent neuropathy.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Abnormal foot morphology
    term:
      id: HP:0001760
      label: Abnormal foot morphology
  evidence:
  - reference: PMID:39680150
    reference_title: "Giant axonal neuropathy (GAN): cross-sectional data on phenotypes, genotypes, and proteomic signature from a German cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Abnormal foot morphology8 (53.3)  Talipes4 (26.7)  Pes planus7 (46.7)"
    explanation: HPO-coded frequency row from the German cohort (8 of 15), supporting the
      FREQUENT band.
- category: Neurologic
  name: Pyramidal signs
  description: >-
    Upper motor neuron signs reflecting central tract involvement.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Abnormal pyramidal sign
    term:
      id: HP:0007256
      label: Abnormal pyramidal sign
  evidence:
  - reference: PMID:39680150
    reference_title: "Giant axonal neuropathy (GAN): cross-sectional data on phenotypes, genotypes, and proteomic signature from a German cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Areflexia11 (73.3) Pyramidal sign2 (13.3) Abnormality of coordination7 (46.7)"
    explanation: HPO-coded frequency row from the German cohort (2 of 15), supporting the
      OCCASIONAL band. The cohort codes this as the generic "pyramidal sign",
      which HP:0007256 carries as an exact synonym.
- category: Neurologic
  name: Delayed gross motor development
  description: >-
    Developmental delay in the motor domain, part of the broader
    neurodevelopmental involvement.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Delayed gross motor development
    term:
      id: HP:0002194
      label: Delayed gross motor development
  evidence:
  - reference: PMID:39680150
    reference_title: "Giant axonal neuropathy (GAN): cross-sectional data on phenotypes, genotypes, and proteomic signature from a German cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Development Delayed gross motor development4 (26.7) Delayed fine motor development2 (13.3)"
    explanation: HPO-coded frequency row from the German cohort (4 of 15), supporting the
      OCCASIONAL band.
- category: Gastrointestinal
  name: Feeding difficulties
  description: >-
    Bulbar involvement produces feeding difficulty as the disease advances.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Feeding difficulties
    term:
      id: HP:0011968
      label: Feeding difficulties
  evidence:
  - reference: PMID:39680150
    reference_title: "Giant axonal neuropathy (GAN): cross-sectional data on phenotypes, genotypes, and proteomic signature from a German cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Abnormal digestive system physiology6 (40.0)  Feeding difficulties4 (26.7)"
    explanation: HPO-coded frequency row from the German cohort (4 of 15), supporting the
      OCCASIONAL band.
- category: Neurologic
  name: Cerebral white matter abnormality
  description: >-
    Periventricular and cerebellar white-matter T2 hyperintensity, sometimes
    described as a leukoencephalopathy - the imaging correlate of the central
    arm of the disease.
  phenotype_term:
    preferred_term: Abnormal cerebral white matter morphology
    term:
      id: HP:0002500
      label: Abnormal cerebral white matter morphology
  evidence:
  - reference: PMID:39680150
    reference_title: "Giant axonal neuropathy (GAN): cross-sectional data on phenotypes, genotypes, and proteomic signature from a German cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Magnetic resonance imaging (MRI) shows high signals on T2-weighted
      sequences in the anterior and posterior periventricular regions as well as
      in the cerebellar white matter, sometimes referred to as
      leukoencephalopathy or leukodystrophy."
    explanation: Describes the white-matter imaging abnormality. No frequency is
      given by the source, so no frequency band is asserted.
genetic:
- name: GAN
  notes: >-
    Biallelic loss-of-function variants in GAN (16q23.2), encoding gigaxonin,
    cause giant axonal neuropathy. Causative variants are distributed
    throughout the gene; a recurrent founder mutation has been described in
    individuals of Mexican descent, and recurrent uniparental isodisomy has
    been reported as a route to biallelic status.
  gene_term:
    preferred_term: GAN
    term:
      id: hgnc:4137
      label: GAN
  relationship_type: CAUSATIVE
  evidence:
  - reference: PMID:11062483
    reference_title: "The gene encoding gigaxonin, a new member of the cytoskeletal BTB/kelch repeat family, is mutated in giant axonal neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We report here identification of the gene GAN, which encodes a
      novel, ubiquitously expressed protein we have named gigaxonin. We found
      one frameshift, four nonsense and nine missense mutations in GAN of GAN
      patients."
    explanation: The gene-discovery study identifying GAN and its mutation
      spectrum in patients.
  - reference: PMID:34114613
    reference_title: "Giant axonal neuropathy: cross-sectional analysis of a large natural history cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We review causative variants distributed throughout the GAN gene
      in this cohort and identify a recurrent founder mutation in individuals
      with GAN of Mexican descent as well as cases of recurrent uniparental
      isodisomy."
    explanation: Describes the variant distribution, a founder allele, and
      uniparental isodisomy as a mechanism reaching biallelic status.
diagnosis:
- name: Molecular genetic testing
  description: >-
    The diagnosis is established in a proband with suggestive clinical findings
    by identifying biallelic pathogenic GAN variants. Molecular confirmation is
    now the definitive test, with biopsy relegated to a supporting role.
  evidence:
  - reference: PMID:20301315
    reference_title: "GAN-Related Neurodegeneration."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The diagnosis of GAN-related neuropathy is established in a
      proband with suggestive findings and biallelic GAN pathogenic variants
      identified by molecular genetic testing."
    explanation: GeneReviews DIAGNOSIS/TESTING statement establishing molecular
      testing as the diagnostic standard.
- name: Nerve conduction studies and electromyography
  description: >-
    Electrophysiology shows a nerve length-dependent sensorimotor neuropathy.
    Sensory nerve action potentials are characteristically very low or absent -
    their recovery was used as an objective outcome measure in the gene therapy
    trial.
  evidence:
  - reference: PMID:38507752
    reference_title: "Intrathecal Gene Therapy for Giant Axonal Neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Peripheral axonal loss in giant axonal neuropathy causes
      progressive sensorimotor neuropathy, as indicated on electrophysiological
      testing and histologic analysis of the peripheral nerves."
    explanation: Establishes electrophysiology and nerve histology as the
      modalities demonstrating the peripheral axonal loss.
  - reference: PMID:38507752
    reference_title: "Intrathecal Gene Therapy for Giant Axonal Neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Between 6 and 24 months after gene transfer, sensory-nerve action
      potential amplitudes increased, stopped declining, or became recordable
      after being absent in 6 participants but remained absent in 8."
    explanation: Shows sensory nerve action potentials are absent or severely
      reduced at baseline in most patients, and usable as a quantitative
      diagnostic and outcome measure.
- name: Brain MRI
  description: >-
    T2-weighted hyperintensity in the periventricular regions and cerebellar
    white matter, sometimes described as a leukoencephalopathy or
    leukodystrophy - the radiological signature of the central arm of the
    disease.
  evidence:
  - reference: PMID:39680150
    reference_title: "Giant axonal neuropathy (GAN): cross-sectional data on phenotypes, genotypes, and proteomic signature from a German cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Magnetic resonance imaging (MRI) shows high signals on T2-weighted
      sequences in the anterior and posterior periventricular regions as well as
      in the cerebellar white matter, sometimes referred to as
      leukoencephalopathy or leukodystrophy."
    explanation: Describes the characteristic MRI findings used diagnostically.
histopathology:
- name: Giant axons on nerve biopsy
  description: >-
    Electron microscopy of sural nerve shows the pathognomonic lesion: focally
    enlarged axons distended by densely packed, disorganized intermediate
    filaments, surrounded by disproportionately thin myelin. Biopsy is now
    supporting rather than required evidence when molecular testing is
    definitive.
  evidence:
  - reference: PMID:29766026
    reference_title: "Development of Intrathecal AAV9 Gene Therapy for Giant Axonal Neuropathy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The pathologic signature of GAN is giant axonal swellings filled
      with disorganized accumulations of IFs."
    explanation: States the defining histopathological lesion.
  - reference: PMID:37137704
    reference_title: "A New Mouse Model of Giant Axonal Neuropathy with Overt Phenotypes and Neurodegeneration Driven by Neurofilament Disorganization."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Sural nerve biopsies of human GAN patients have shown the presence
      of giant axons filled with IFs, a characteristic feature of GAN disease"
    explanation: States the human sural nerve biopsy finding specifically. The
      quoted sentence is this paper's summary of the human literature, not its
      own mouse data, hence HUMAN_CLINICAL.
prevalence:
- population: Worldwide
  measure_type: CASES_IN_LITERATURE
  prevalence_class: ULTRA_RARE
  notes: >-
    Approximately 75 families reported worldwide. No defensible population
    prevalence or incidence rate, carrier frequency, or sex ratio has been
    established for this disease, so no rate_per_100000 is recorded.
  evidence:
  - reference: PMID:39680150
    reference_title: "Giant axonal neuropathy (GAN): cross-sectional data on phenotypes, genotypes, and proteomic signature from a German cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Thus far, this neurological condition has been reported in
      approximately 75 families worldwide"
    explanation: States the total number of ascertained families, which is the
      only defensible occurrence figure for this disease. Note this counts
      families, not individuals.
experimental_models:
- name: GAN patient dermal fibroblasts (vimentin aggregate assay)
  experimental_model_type: PRIMARY_CELL_CULTURE
  description: >-
    Primary skin fibroblasts from GAN patients accumulate vimentin intermediate
    filament aggregates, providing an accessible non-neural readout of the
    generalized defect and the assay used to demonstrate rescue by GAN gene
    transfer.
  modeled_mechanisms:
  - target: Intermediate Filament Aggregation
    relationship: RECAPITULATES
    fidelity: HIGH
    description: >-
      Patient-derived cells reproduce the defining cellular lesion in the
      patient's own genetic background.
    limitations: >-
      Fibroblasts report the vimentin arm of a generalized intermediate filament
      defect and cannot model the axonal geometry, giant axon formation, or the
      neuronal degeneration that determine the clinical phenotype.
    readouts:
    - name: Proportion of cells displaying vimentin IF aggregates
      target: Intermediate Filament Aggregation
      direction: RESTORED
      interpretation: >-
        Aggregate-bearing cell counts fall after delivery of a normal GAN
        transgene, tying the cellular phenotype to gigaxonin deficiency.
      evidence:
      - reference: PMID:23316953
        reference_title: "Restoration of cytoskeleton homeostasis after gigaxonin gene transfer for giant axonal neuropathy."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: "Treatment of primary skin fibroblast cultures from three
          different GAN patients with an adeno-associated virus type 2 (AAV2)
          vector containing a normal human GAN transgene significantly reduced
          the number of cells displaying vimentin IF aggregates."
        explanation: Reports the measurement and its direction after gene
          transfer.
    evidence:
    - reference: PMID:23585478
      reference_title: "Giant axonal neuropathy-associated gigaxonin mutations impair intermediate filament protein degradation."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "In GAN, aggregates of intermediate filaments (IFs) represent the
        main pathological feature detected in neurons and other cell types,
        including patients' dermal fibroblasts."
      explanation: Establishes that patient fibroblasts carry the same defining
        lesion, which is what makes them informative for this node.
animal_models:
- name: Gan knockout mouse
  species: Mouse
  genotype: Gan-/-
  publication: PMID:29766026
  description: >-
    Gigaxonin-null mice accumulate neuronal intermediate filaments and show
    peripheral nerve pathology and rotarod deficits, and were the vehicle for
    preclinical intrathecal AAV9 gene-transfer studies.
  modeled_mechanisms:
  - target: Intermediate Filament Aggregation
    relationship: PARTIALLY_RECAPITULATES
    fidelity: LOW
    description: >-
      The knockout reproduces intermediate filament accumulation and peripheral
      nerve pathology, and these are reversible by GAN gene transfer, which is
      what made it usable for preclinical gene-transfer work.
    limitations: >-
      Downgraded from RECAPITULATES/MODERATE on the strength of PMID:41402936,
      which reports that the early knockout strains failed to reproduce the
      severity and histopathology of human disease: mild, late-onset (>12
      months) symptoms with no overt degeneration and, critically, no giant
      axons and no neurofilament compaction - the defining human lesions.
      Phenotype also varies with genetic background. Inferences about the giant
      axon and CNS arms of the disease should use the A49E knock-in instead.
    evidence:
    - reference: PMID:41402936
      reference_title: "Disease mutation in gigaxonin-E3 ligase recapitulates giant axonal neuropathy in mice."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Indeed, the homozygous KO mice exhibit mild symptoms with late
        onset (> 12 months of age), no overt degeneration, absence of giant
        axons and compaction of NFs, which is seen in patients"
      explanation: Directly limits what the knockout can support - it lacks the
        defining human lesions - which is why the relationship is
        PARTIALLY_RECAPITULATES rather than RECAPITULATES.
    - reference: PMID:23585478
      reference_title: "Giant axonal neuropathy-associated gigaxonin mutations impair intermediate filament protein degradation."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Using fibroblasts from patients and normal individuals, as well
        as Gan-/- mice, we demonstrated that gigaxonin was responsible for the
        degradation of vimentin IFs."
      explanation: The knockout was used to establish gigaxonin's degradation
        role, supporting its relevance to this node.
    readouts:
    - name: Neuronal intermediate filament accumulation and sciatic nerve ultrastructure
      target: Intermediate Filament Aggregation
      direction: RESTORED
      interpretation: >-
        Intrathecal gene transfer preserved nerve ultrastructure and reduced
        intermediate filament accumulation, linking the aggregation node to
        gigaxonin dose.
      evidence:
      - reference: PMID:29766026
        reference_title: "Development of Intrathecal AAV9 Gene Therapy for Giant Axonal Neuropathy."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "IT delivery of AAV9/JeT-GAN in aged GAN KO mice preserved
          sciatic nerve ultrastructure, reduced neuronal IF accumulations and
          attenuated rotarod dysfunction."
        explanation: Reports the measured structural and functional readouts in
          the knockout.
- name: GAN A49E knock-in mouse
  species: Mouse
  genotype: GAN A49E/A49E knock-in
  publication: PMID:41402936
  description: >-
    A knock-in of a disease-causing GAN missense mutation rather than a gene
    deletion. Unlike the earlier knockout strains it produces an overt
    phenotype - early sensory-motor deficits and ataxia, giant axons,
    demyelination, and the neurofilament compaction and disorganization seen in
    patients - making it the first rodent model to reproduce the histological
    hallmarks. It also reveals neuromuscular junction and muscle involvement,
    and a sex bias with females more severely affected that has no established
    human counterpart.
  modeled_mechanisms:
  - target: Giant Axon Formation
    relationship: RECAPITULATES
    fidelity: HIGH
    description: >-
      Reproduces the pathognomonic lesion - giant axons with compacted,
      disorganized neurofilaments - which the knockout strains do not.
    limitations: >-
      Carries one specific missense allele (A49E), so it models the dominant
      mechanism of gigaxonin protein instability rather than the full mutational
      spectrum. The female-biased severity has no established human counterpart.
    readouts:
    - name: Giant axons and neurofilament compaction across the nervous system
      target: Giant Axon Formation
      direction: INCREASED
      interpretation: >-
        Presence of the human histological hallmark, absent from prior knockout
        models, is what makes this strain informative for this node.
      evidence:
      - reference: PMID:41402936
        reference_title: "Disease mutation in gigaxonin-E3 ligase recapitulates giant axonal neuropathy in mice."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "GANA49E/A49E mice exhibit early sensory-motor deficits and
          ataxia, giant axons and demyelination which, together with increased
          abundance, dramatic compaction and disorganization of neurofilaments
          across the nervous system, mimics the human disease."
        explanation: Reports the histological and behavioural readouts in this
          strain.
    evidence:
    - reference: PMID:41402936
      reference_title: "Disease mutation in gigaxonin-E3 ligase recapitulates giant axonal neuropathy in mice."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Altogether, the GANA49E strain provides the first robust rodent
        model for GAN, recapitulating the symptoms and histological hallmarks of
        the human pathology."
      explanation: The authors' own assessment that this strain recapitulates
        the disease, which is the basis for treating it as informative here.
treatments:
- name: Intrathecal scAAV9/JeT-GAN gene transfer
  description: >-
    Self-complementary AAV9 carrying a codon-optimized human GAN transgene under
    the JeT promoter, delivered by lumbar intrathecal infusion to target spinal
    motor neuron and dorsal root ganglion cell bodies. Evaluated in a phase 1
    dose-escalation study (NCT02362438) in 14 children. Results were mixed and
    dose-dependent: the 1.8x10^14 vg dose met the prespecified efficacy
    threshold for slowing motor decline, but the highest dose did not, and
    adverse events occurred. This is an investigational therapy, not an
    established standard of care.
  therapeutic_modality: GENE_THERAPY
  treatment_term:
    preferred_term: Gene Therapy
    term:
      id: NCIT:C15238
      label: Gene Therapy
  target_mechanisms:
  - target: Gigaxonin Loss of Function
    treatment_effect: RESTORES
    description: >-
      The transgene restores gigaxonin expression, addressing the primary
      molecular defect rather than a downstream consequence.
    evidence:
    - reference: PMID:29766026
      reference_title: "Development of Intrathecal AAV9 Gene Therapy for Giant Axonal Neuropathy."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "This strategy conferred sustained wild-type gigaxonin expression
        across the PNS and CNS for at least 1 year in mice."
      explanation: Demonstrates that the vector restores the missing protein,
        which is the mechanism by which it targets this node.
  evidence:
  - reference: PMID:38507752
    reference_title: "Intrathecal Gene Therapy for Giant Axonal Neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Intrathecal gene transfer with scAAV9/JeT-GAN for giant axonal
      neuropathy was associated with adverse events and resulted in a possible
      benefit in motor function scores and other measures at some vector doses
      over a year."
    explanation: The trial's own conclusion is deliberately hedged — possible
      benefit at some doses, with adverse events — so this supports the
      treatment only partially.
  - reference: PMID:38507752
    reference_title: "Intrathecal Gene Therapy for Giant Axonal Neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Between 6 and 24 months after gene transfer, sensory-nerve action
      potential amplitudes increased, stopped declining, or became recordable
      after being absent in 6 participants but remained absent in 8."
    explanation: Reports the electrophysiological outcome, including the
      non-responding majority, as an objective measure alongside the motor
      score.
- name: Multidisciplinary supportive care
  description: >-
    No disease-modifying therapy is established. Management is supportive and
    multidisciplinary, directed at the individual's clinical findings, with the
    goal of optimizing intellectual and physical development.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: Supportive Care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:20301315
    reference_title: "GAN-Related Neurodegeneration."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Supportive care is focused on managing the clinical findings of
      the individual, and often involves a team including neurologists,
      orthopedic surgeons, physiotherapists, occupational and physical
      therapists, psychologists, and speech-language pathologists."
    explanation: GeneReviews management recommendation for the disease.
clinical_trials:
- name: NCT02362438
  phase: PHASE_I
  status: COMPLETED
  description: >-
    Intrathecal dose-escalation study of scAAV9/JeT-GAN in children with giant
    axonal neuropathy; safety was the primary end point, with change in the
    32-item Motor Function Measure total percent score as key secondary
    clinical end point.
  evidence:
  - reference: PMID:38507752
    reference_title: "Intrathecal Gene Therapy for Giant Axonal Neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We conducted an intrathecal dose-escalation study of
      scAAV9/JeT-GAN (a self-complementary adeno-associated virus-based gene
      therapy containing the GAN transgene) in children with giant axonal
      neuropathy. Safety was the primary end point."
    explanation: Describes the trial design and primary end point.
  - reference: PMID:38507752
    reference_title: "Intrathecal Gene Therapy for Giant Axonal Neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Participants older than 6 years of age with genetically confirmed
      giant axonal neuropathy were enrolled from April 2015 through August 2020."
    explanation: Records the enrollment window, which closed in August 2020.
  - reference: clinicaltrials:NCT02362438
    reference_title: "A Phase I Study of Intrathecal Administration of scAAV9/JeT-GAN for the Treatment of Giant Axonal Neuropathy"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Participants will have a total of about 27 visits, weekly,
      monthly, and then yearly over 15 years."
    explanation: The registry record's own long-term follow-up schedule.
  notes: >-
    Status corrected from ACTIVE_NOT_RECRUITING to COMPLETED. The ClinicalTrials.gov
    v2 API reports overallStatus COMPLETED with an ACTUAL completion date of
    2026-04-10 (record last updated 2026-08-14, queried 2026-08-20). The earlier
    value was inferred from the 2024 publication describing the study as ongoing
    with enrollment closed - an inference that was already stale when it was
    made. No evidence item quotes the status because the cached registry record
    predates the completion and carries no recruitment-status field; the status
    is taken from the live registry, recorded here rather than as a fabricated
    snippet.
discussions:
- discussion_id: gan_knockout_model_fidelity
  kind: HUMAN_MODEL_MISMATCH
  prompt: >-
    Does the preclinical evidence base for GAN - built largely on Gan-knockout
    mice that lack giant axons and neurofilament compaction - support inference
    about the human disease, and does the A49E knock-in change what earlier
    knockout results can be taken to show?
  attaches_to:
  - pathophysiology#Giant Axon Formation
  rationale: >-
    The gene-transfer work that supported the first-in-human trial was performed
    largely in knockout strains now reported to lack the two defining human
    lesions. That is a translational-validity question rather than a gap in
    evidence: the mouse results exist and are internally sound, but the model
    was missing the pathology the therapy is meant to reverse. The A49E knock-in
    reproduces those lesions and so offers a way to test whether the earlier
    conclusions hold. Its female-biased severity has no established human
    counterpart and should not be carried into human claims.
  evidence:
  - reference: PMID:41402936
    reference_title: "Disease mutation in gigaxonin-E3 ligase recapitulates giant axonal neuropathy in mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Unlike previous GAN knock-out mice which show no overt phenotype,
      GANA49E/A49E mice exhibit early sensory-motor deficits and ataxia"
    explanation: States the contrast between the knockout strains and the
      knock-in that makes this a model-fidelity question.
  proposed_experiments:
  - experiment_id: gan_a49e_gene_transfer_replication
    name: Replicate intrathecal AAV9 GAN gene transfer in the A49E knock-in
    description: >-
      Repeat the preclinical intrathecal scAAV9/JeT-GAN dosing in GAN A49E/A49E
      mice and score giant axon burden and neurofilament compaction - endpoints
      unavailable in the knockout strains - alongside the rotarod and nerve
      ultrastructure measures used originally, powered to detect the reported
      sex difference.
- discussion_id: gan_phenotypic_continuum_determinants
  kind: KNOWLEDGE_GAP
  prompt: >-
    What determines position on the GAN phenotypic continuum — why do some
    individuals with biallelic GAN loss-of-function variants develop classic
    infantile multisystem neurodegeneration while others have a milder,
    later-onset, predominantly peripheral CMT-like course?
  attaches_to:
  - pathophysiology#Progressive Neurological Decline
  rationale: >-
    Both ends of the continuum share the same causal mechanism — biallelic GAN
    loss of function — yet differ markedly in age of onset, rate of
    progression, and whether the central nervous system is involved at all. The
    natural history cohort characterized the milder subcohort but the
    determinants of that divergence (residual gigaxonin function by genotype,
    modifier alleles, or another factor) are not established, which matters
    directly for prognosis and for trial stratification. The obvious candidate
    explanation — genotype — has been looked for and not found: no mutation
    hotspot exists and no apparent genotype-phenotype correlation has been
    demonstrated, so this is an open question rather than an unexamined one.
  evidence:
  - reference: PMID:39680150
    reference_title: "Giant axonal neuropathy (GAN): cross-sectional data on phenotypes, genotypes, and proteomic signature from a German cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "An obvious mutation hotspot does not exist, and there is no
      apparent correlation between genotype and phenotype."
    explanation: Establishes that the genotype-based explanation for continuum
      position has been sought and not found, which is what makes this a
      genuine knowledge gap rather than an unasked question.
  proposed_experiments:
  - experiment_id: gan_genotype_continuum_correlation
    name: Genotype-to-continuum-position correlation in the natural history cohort
    description: >-
      Correlate genotype class (null/null versus genotypes predicted to retain
      residual gigaxonin, e.g. missense) with continuum position and rate of
      MFM-32 decline in the prospective natural history cohort, using
      cross-reactive immunologic material status as an independent measure of
      residual protein.
notes: >-
  Lump/split decision: curated as a single Disease entry at MONDO:0009749
  (giant axonal neuropathy 1), the gene-specific term, with the severe and
  CMT-like presentations as has_subtypes rather than separate entries.


  The entry is deliberately NOT curated at the MONDO parent MONDO:0000128
  (giant axonal neuropathy). That term is an OMIM phenotypic-series grouping
  spanning two different genes: this entry's GAN/gigaxonin disease
  (MONDO:0009749) and the distinct DCAF8 disease giant axonal neuropathy 2
  (MONDO:0012411). Curating at the parent would conflate two genes, so the
  gene-specific child is the correct level.


  Within MONDO:0009749, GeneReviews treats the whole severity range as one
  continuum ("GAN-related neurodegeneration") arising from one mechanism -
  biallelic GAN loss of function - which is why the severe and mild
  presentations are modeled as subtypes rather than as separate entries.


  Naming caution: the "CMT-like GAN" subtype here is the mild end of the
  GAN/gigaxonin continuum, NOT the DCAF8 disease MONDO:0012411, whose own
  synonyms include "CMT2 with giant axons" and which is genuinely classified
  under CMT2. The two are different genes and different MONDO terms despite the
  similar phrasing.


  No datasets are recorded. `just discover-datasets` returned only GENE_ONLY
  candidates, every one of which was a false match on the string "GAN" as the
  Gubra-Amylin NASH ("GAN diet") mouse model rather than the GAN gene — NASH,
  obesity and alcoholic liver disease studies with no relation to this disease.
  Relevance triage rejected all of them; this is the Named Entity Confusion
  failure mode reached through dataset search.


  Curated with falcon deep research plus GeneReviews and primary literature.

📚

References & Deep Research

References

1

PMID:20301315

GAN-Related Neurodegeneration.

No top-level findings curated for this source.

Deep Research

1

Falcon ▸

Disease Characteristics Research Template

Edison Scientific Literature 31 citations 2026-08-20T04:26:19.118031

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

Disease Name: Giant Axonal Neuropathy 1
MONDO ID: (if available)
Category: Mendelian

Research Objectives

Please provide a comprehensive research report on Giant Axonal Neuropathy 1 covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

What is the disease? Provide a concise overview.
What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
What are the common synonyms and alternative names?
Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
Risk Factors:

Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
Genetic risk factors (causal variants, susceptibility loci, modifier genes)
Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
Protective Factors:

Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
Genetic protective factors (protective variants, modifier alleles)
Environmental protective factors (diet, lifestyle, exposures that reduce risk)
Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
Pathogenic Variants:
Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
Variant type/class (missense, frameshift, nonsense, splice-site, structural)
Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
Functional consequences (loss of function, gain of function, dominant negative)
Modifier Genes: Genes that modify disease severity or expression
Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

Search first: CDC databases, WHO, PubMed, NHANES
Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc
Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

Search first: Gene Ontology (GO), Reactome, KEGG, PubMed
Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

Search first: ImmPort, Immunome Database, IEDB, Gene Ontology
Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

Search first: PubMed, Gene Ontology, Reactome
Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

Search first: BRENDA, UniProt, KEGG, OMIM, PubMed
Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Molecular Profiling (if available):
Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
Advanced Technologies (if applicable):
Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

Organ Level:
Primary organs directly affected
Secondary organ involvement (complications, secondary effects)
Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
Tissue and Cell Level:
Specific tissue types affected (epithelial, connective, muscle, nervous)
Specific cell populations targeted (with Cell Ontology terms)

Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
Subcellular Level:
Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
Localization:
Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

Onset:
Typical age of onset (congenital, pediatric, adult, geriatric)
Onset pattern (acute, subacute, chronic, insidious)

Search first: OMIM, Orphanet, HPO, PubMed
Progression:
Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
Progression rate (rapid, slow, variable)
Disease course pattern (episodic, relapsing-remitting, progressive, stable)
Disease duration (self-limited, chronic lifelong)

Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
Patterns:
Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

Epidemiology:
Prevalence (cases per 100,000 at given time)
Incidence (new cases per 100,000 per year)

Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
For Genetic Etiology:
Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
Population Demographics:
Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
Geographic distribution of specific variants
Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

Clinical Tests:
Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
Genetic Testing:

Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen
Overview of recommended genetic testing approach
Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
FISH > Search first: ClinVar, cytogenetics databases, PubMed
Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
Omics-Based Diagnostics (if applicable):
RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
Clinical Criteria:
Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
Screening:
Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

Survival and Mortality:
Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
Morbidity and Function:
Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
Disease Course:
Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
Prediction:
Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

Pharmacotherapy:
Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
Advanced Therapeutics:
Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
Surgical and Interventional:
Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
Supportive and Rehabilitative:
Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
Experimental:
Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
Treatment Outcomes:
Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
Treatment Strategy:
Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

13. Prevention

Prevention Levels:
Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
Immunization: Vaccine strategies (if applicable)

Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database
Screening and Early Detection:
Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
Behavioral Interventions: Lifestyle modifications to reduce risk

Search first: CDC, WHO, behavioral intervention databases, Cochrane Library
Counseling: Genetic counseling (risk assessment, family planning guidance)

Search first: NSGC resources, ACMG guidelines, GeneReviews
Public Health:
Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
Prophylaxis: Preventive medications or procedures

Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

Taxonomy: Species affected (with NCBI Taxon identifiers)

Search first: NCBI Taxonomy
Breed: Specific breeds affected (with VBO identifiers if applicable)

Search first: VBO (Vertebrate Breed Ontology)
Gene: Orthologous genes in other species (with NCBI Gene IDs)

Search first: NCBI Gene
Natural Disease:
Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
Comparative Biology:
Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
Transmission (if applicable):
Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

Model Types:
Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
Genetic Models:
Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
Model Characteristics:
Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
Applications:
Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
Resources:
Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

Cite primary literature (PMID preferred) for all mechanistic and clinical claims
Prioritize recent reviews and landmark papers
Include direct quotes from abstracts where possible to support key statements
Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (NCIT terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Giant Axonal Neuropathy 1 (GAN1): comprehensive disease-characteristics report

Scope and evidence note. GAN is ultra-rare, so most clinical knowledge comes from aggregated disease resources, case series, a 2021 natural-history cohort, a 15-person German cohort published online in December 2024/print 2025, and one 14-participant phase 1 trial—not EHR-scale population data. Mechanistic evidence is largely from patient cells, engineered human cells, and animal models. Frequencies below should therefore not be interpreted as population prevalence.

Topic	Key evidence-based findings	Identifiers / exact numbers	Evidence type	Source
Disease identity / inheritance	Giant axonal neuropathy (GAN; GAN1) is a rare pediatric neurodegenerative disorder affecting central and peripheral nervous systems; inheritance is autosomal recessive and due to biallelic loss-of-function variants in GAN encoding gigaxonin. Distinct early-onset severe and milder later-onset CMT-like phenotypes are described.	OMIM/MIM #256850; GAN at 16q23.2 (also reported as 16q24.1 in older literature); MeSH D056768; >75 families known to investigators.	Human clinical / disease resource / review	DOI: 10.3390/jpm13010091; DOI: 10.1056/NEJMoa2307952; ClinicalTrials.gov NCT02362438 (shirakaki2022geneticapproachesfor pages 1-2, gangfuss2025giantaxonalneuropathy pages 1-2, NCT02362438 chunk 1, NCT02362438 chunk 3, bharuchagoebel2024intrathecalgenetherapy pages 1-3)
Core phenotype & natural history	Typical onset at 3–5 years with clumsy or unsteady gait/sensory ataxia, progressive distal>proximal weakness, areflexia, hypotonia, gait disturbance, and characteristic tightly curled/frizzy hair; later features include cerebellar dysfunction, vision loss, contractures, respiratory complications, and loss of ambulation. Most patients become wheelchair dependent by the second decade and often die from pulmonary/respiratory complications by the second to third decade.	German cohort (n=15): gait disturbance 100%, muscle weakness 100%, hypotonia 93.3%, curly/frizzy hair 93.3%, distal weakness 80%, abnormal reflexes 80%, areflexia 73.3%, frequent falls 66.7%, joint contractures 53.3%, respiratory abnormality 53.3%, intellectual disability 26.7%.	Human cohort / review / natural history	DOI: 10.1007/s00415-024-12744-z; DOI: 10.3390/jpm13010091; ClinicalTrials.gov NCT01503125 (gangfuss2025giantaxonalneuropathy pages 5-6, gangfuss2025giantaxonalneuropathy pages 6-8, NCT01503125 chunk 1, shirakaki2022geneticapproachesfor pages 2-4, shirakaki2022geneticapproachesfor pages 4-6, bharuchagoebel2024intrathecalgenetherapy pages 3-5, renganathan2023gigaxoninisrequired pages 1-2)
Diagnosis	Diagnosis integrates clinical phenotype plus molecular confirmation. Electrophysiology shows length-dependent sensorimotor neuropathy with markedly reduced or absent CMAP/SNAP amplitudes; EMG shows chronic denervation/neuropathic changes. MRI often shows cerebellar and periventricular white-matter hyperintensities/leukoencephalopathy. Nerve/skin/sural biopsy or EM shows enlarged axons packed with neurofilaments and thin/decreased myelin sheaths.	Trial/natural-history assessments included NCS, MUNE, SSEP, BAER, PFT, MRI, nerve biopsy, skin biopsy. Inclusion in interventional trial required pathogenic variants on both GAN alleles.	Human clinical / diagnostic / trial protocol	DOI: 10.3390/jpm13010091; ClinicalTrials.gov NCT01503125, NCT02362438 (NCT01503125 chunk 1, shirakaki2022geneticapproachesfor pages 2-4, NCT02362438 chunk 1, NCT02362438 chunk 2)
Molecular mechanism	Gigaxonin is a low-abundance BTB/BACK/Kelch adaptor for a CUL3-RBX1 E3 ubiquitin ligase complex. Loss of gigaxonin impairs ubiquitination/degradation of intermediate filament proteins, causing IF/neurofilament accumulation, giant axons, axonal dysfunction, and multisystem cytoskeletal pathology. Gigaxonin also regulates autophagosome production via ATG16L1 turnover and broader proteostasis.	Gigaxonin protein ~65 kDa; GAN gene has 11 exons; variant counts reported as 89 (2022 database summary) and ~100–150 across broader literature.	Mechanistic review / in vitro / animal	DOI: 10.3390/jpm13010091; DOI: 10.1172/jci.insight.127751 (chen2020gigaxoninglycosylationregulates pages 2-3, shirakaki2022geneticapproachesfor pages 6-7, shirakaki2022geneticapproachesfor pages 1-2)
2023 mechanistic advances	1) CRL3^gigaxonin–USP15 pathway shown to govern destruction of NEFL and INA; Kelch-domain variants L309R, R545C, C570Y disrupted substrate binding and caused NF accumulation. 2) Loss of gigaxonin was shown to dramatically inhibit intermediate-filament transport along microtubules by kinesin-1, with >20-fold increase in soluble vimentin oligomers in KO cells. 3) New overt mouse model (Gan−/−;TgPer) linked NF disorganization to sensory-motor deficits, cognitive deficits, neuroinflammation, and neuron loss.	PNAS 2023; FASEB J 2023; J Neurosci 2023. Gan−/−;TgPer mice had giant axons ≥160 μm².	Mechanistic human-cell / mouse model	DOI: 10.1073/pnas.2306395120; DOI: 10.1096/fj.202202119R; DOI: 10.1523/JNEUROSCI.1959-22.2023 (nath2023anewmouse pages 1-2, park2023thecrl3gigaxoninubiquitin pages 1-2, renganathan2023gigaxoninisrequired pages 1-2)
2024 scAAV9/JeT-GAN gene-therapy trial	First-in-human open-label intrathecal dose-escalation study of scAAV9/JeT-GAN in children with genetically confirmed GAN. A single dose was given to 14 participants across four dose levels. Primary endpoint: safety. Key secondary endpoint: ≥95% posterior probability of slowing decline in MFM-32 total percent score at 1 year versus pretreatment slope.	Doses: 3.5×10^13 vg (n=2), 1.2×10^14 vg (n=4), 1.8×10^14 vg (n=5), 3.5×10^14 vg (n=3). Median observation 68.7 months (range 8.6–90.5). Serious AEs 48, with 1 possibly treatment-related (fever). Total AEs 682, with 129 possibly treatment-related. Mean pretreatment MFM-32 slope −7.17 percentage points/year (95% credible interval −8.36 to −5.97). Posterior mean slope changes at 1 year: −0.54, 3.23, 5.32, 3.43 percentage points by ascending dose. Posterior probabilities for slowing slope: 44%, 92%, 99%, 90%; efficacy threshold met at 1.8×10^14 vg. Sensory-nerve action potentials increased/stabilized/became recordable in 6 participants and remained absent in 8.	Interventional phase 1 human trial	DOI: 10.1056/NEJMoa2307952; ClinicalTrials.gov NCT02362438; PMID 38507752 (NCT02362438 chunk 1, NCT02362438 chunk 2, bharuchagoebel2024intrathecalgenetherapy pages 3-5, bharuchagoebel2024intrathecalgenetherapy pages 1-3, bharuchagoebel2024intrathecalgenetherapy pages 5-7)
Current standard care	No approved curative therapy; management is supportive and multidisciplinary. Reported measures include physical therapy, occupational therapy, speech therapy, aquatic therapy, bracing/orthotics, pain control, respiratory monitoring/support, feeding support, and orthopedic management as needed.	Reviews note need for ventilation/tracheostomy and feeding tube in advanced disease; trial exclusion criteria used FVC ≤50% predicted or daytime ventilator dependence, reflecting major respiratory involvement in advanced GAN.	Review / supportive care / trial protocol	DOI: 10.3390/jpm13010091; ClinicalTrials.gov NCT02362438 (shirakaki2022geneticapproachesfor pages 1-2, NCT02362438 chunk 1, NCT02362438 chunk 2, shirakaki2022geneticapproachesfor pages 8-10)
Main model systems	Multiple disease models are in use: Gan knockout mice, Gan−/−;TgPer mice, disease-mutation GANA49E/A49E mice, patient-derived fibroblasts, CRISPR GAN−/− SH-SY5Y cells, iPSC-derived motor neurons, and DRG neuron models. Preclinical intrathecal AAV9 studies in Gan-knockout rodents supported translation to human trials; rat studies also showed retinal degeneration relevant to disease breadth.	Gan−/−;TgPer model shows early sensory-motor deficits and later cognitive deficits; GANA49E/A49E mouse reportedly recapitulates ataxia, giant axons, demyelination, NF disorganization. iPSC motor-neuron studies showed IF accumulation rescued by gigaxonin restoration.	Mouse / rat / human cell / iPSC / preclinical gene therapy	DOI: 10.1523/JNEUROSCI.1959-22.2023; DOI: 10.1186/s40478-025-02138-1; DOI: 10.1172/jci.insight.127751; ClinicalTrials.gov NCT02362438 references preclinical AAV work (lienard2026diseasemutationin pages 1-2, nath2023anewmouse pages 1-2, shirakaki2022geneticapproachesfor pages 11-12)

Table: This table condenses high-value evidence for Giant Axonal Neuropathy across disease definition, phenotype, diagnosis, mechanism, recent research, clinical trial results, standard care, and model systems. It is designed as a compact reference for building a disease knowledge-base entry with source-linked quantitative details.

1. Disease information

Giant axonal neuropathy is a childhood-onset, progressive, autosomal-recessive neurodegenerative disorder affecting both the peripheral and central nervous systems. Its defining pathology is axonal swelling caused by densely packed, disorganized intermediate filaments, hence “giant axons.” Two ends of a spectrum are recognized: a severe classical early-onset polysystemic phenotype and a later-onset, slower Charcot–Marie–Tooth (CMT)-like axonal neuropathy. (gangfuss2025giantaxonalneuropathy pages 1-2, bharuchagoebel2024intrathecalgenetherapy pages 3-5)

Identifiers and terminology

OMIM/MIM: 256850.
MeSH: D056768, Giant Axonal Neuropathy.
MONDO: commonly represented as giant axonal neuropathy; the exact MONDO accession should be verified against the current MONDO release before database import because it was not returned directly by the retrieved sources.
Orphanet: an Orphanet entity exists, but the numeric ORPHA identifier was not independently recovered here and should likewise be release-verified.
ICD: no GAN-specific ICD-10-CM code was substantiated. Coding generally falls under hereditary/other specified polyneuropathy; use the current national ICD or ICD-11 browser rather than assigning an unverified disease-specific code.
Synonyms: giant axonal neuropathy; GAN; GAN1; giant axonal neuropathy with curly/kinky hair; giant neuroaxonal neuropathy; severe classical GAN; GAN-related CMT-like neuropathy. “Neuroaxonal dystrophy” is a differential category, not a fully interchangeable name.

The trial registry classifies GAN under hereditary sensory and motor neuropathy, heredodegenerative disease, polyneuropathy, and inborn genetic disease. (NCT02362438 chunk 3)

2. Etiology

Causal and genetic factors

GAN is caused by biallelic germline loss-of-function variants in GAN, encoding gigaxonin. Reported variants include missense, nonsense, frameshift/deletion, and splice-altering alleles distributed across the gene. Counts differ by database and publication date: 89 disease-associated variants were summarized in 2022, whereas broader reviews report roughly 100–150 variants. These counts should not be conflated with the number classified as pathogenic under current ACMG/AMP criteria. (lienard2026diseasemutationin pages 1-2, shirakaki2022geneticapproachesfor pages 6-7, shirakaki2022geneticapproachesfor pages 1-2)

Pathogenicity is primarily recessive loss of function through absent or unstable protein, reduced transcript, protein misfolding, or impaired substrate recognition. Kelch-domain variants such as p.Leu309Arg, p.Arg545Cys, and p.Cys570Tyr disrupted binding to NEFL and INA experimentally. The 2020 Chinese case identified compound-heterozygous c.236C>T (p.Ser79Leu) and c.1466C>G (p.Thr489Ser) variants, with the latter then novel. (park2023thecrl3gigaxoninubiquitin pages 1-2)

Risk, protective, and modifying factors

Established risk: two pathogenic GAN alleles; consanguinity increases the probability of homozygosity. In the German series, parental relatedness was reported in five of ten families. (gangfuss2025giantaxonalneuropathy pages 1-2, gangfuss2025giantaxonalneuropathy pages 6-8)
Family history: may be absent because recessive disease can occur in a single sibship.
Environmental/infectious risk: none established. GAN is not caused by toxins, infection, lifestyle, or occupational exposure.
Protective variants/factors: no validated protective GAN allele, diet, drug, or lifestyle intervention is known.
Potential gene–environment/metabolic interaction: gigaxonin is O-GlcNAcylated in a nutrient-responsive manner. Mass spectrometry identified nine candidate sites, with Ser272 and Thr277 important for intermediate-filament turnover. Because O-GlcNAc depends on glucose, glutamine, acetyl-CoA, uridine, and ATP availability, this provides a plausible metabolic modifier mechanism, but it is cellular evidence, not proof that diet changes human disease severity. (chen2020gigaxoninglycosylationregulates pages 2-3)

No replicated modifier gene or clinically actionable epigenetic signature has been established.

3. Phenotypes

The phenotype is progressive and multisystemic. Suggested HPO mappings should be validated against the current HPO release.

Phenotype	Character/course	Frequency evidence	Suggested HPO term
Gait disturbance/sensory ataxia	Usually first recognized at 3–5 years; chronic progressive	100% in German n=15 cohort	Abnormal gait HP:0001288; sensory ataxia HP:0002066
Muscle weakness	Distal before proximal; severe and progressive	100%; distal weakness 80%	Muscle weakness HP:0001324; distal muscle weakness HP:0002460
Hypotonia	Childhood onset, usually progressive with neuropathy	93.3%	Hypotonia HP:0001252
Areflexia/abnormal reflexes	Length-dependent peripheral neuropathy	Areflexia 73.3%; abnormal reflexes 80%	Areflexia HP:0001284
Curly/kinky/frizzy hair	Characteristic but not obligatory	93.3%	Kinky hair HP:0002224
Frequent falls	Early functional manifestation	66.7%	Frequent falls HP:0002527
Contractures	Secondary to weakness/immobility	53.3%	Joint contracture HP:0034392
Respiratory abnormality	Later-stage weakness/pulmonary complications	53.3%	Respiratory insufficiency HP:0002093
Cerebellar dysfunction	Ataxia, dysmetria; progressive CNS disease	Common qualitatively	Cerebellar ataxia HP:0001251
Pyramidal signs	CNS tract involvement; variable	Variable	Babinski sign HP:0003487 / spasticity HP:0001257
Cognitive/developmental involvement	Developmental delay, intellectual decline; variable	Intellectual disability and gross-motor delay each 26.7% in one cohort	Intellectual disability HP:0001249; gross motor delay HP:0002194
Cranial/ocular involvement	Facial weakness, ophthalmoplegia and later visual loss	Variable	Facial weakness HP:0002058; ophthalmoplegia HP:0000602; visual impairment HP:0000505
Skeletal deformity	Pes planus, kyphoscoliosis, muscle wasting	Variable	Pes planus HP:0001763; scoliosis HP:0002650; muscle atrophy HP:0003202

The German cohort reported gait disturbance and weakness in all 15 patients, hypotonia and frizzy hair in 14/15, distal weakness in 12/15, areflexia in 11/15, falls in 10/15, and respiratory abnormalities and contractures in 8/15. (gangfuss2025giantaxonalneuropathy pages 5-6)

Quality of life. No validated GAN-specific EQ-5D, SF-36, PROMIS, or utility-value dataset was identified. Nevertheless, progressive falls, loss of independent ambulation, upper-limb impairment, communication/swallowing difficulty, respiratory support, and caregiver dependence imply profound mobility, self-care, educational, and psychosocial burden. Trial investigators use the MFM-32, modified Friedreich Ataxia Rating Scale, and Neuropathy Impairment Score rather than a GAN-specific quality-of-life instrument. (bharuchagoebel2024intrathecalgenetherapy pages 5-7)

4. Genetic and molecular information

GAN/gigaxonin. GAN contains 11 exons and encodes an approximately 65-kDa BTB/BACK/Kelch protein. The N-terminal BTB domain binds CUL3/RBX1; BACK contributes complex architecture and ATG16L1 interaction; the C-terminal Kelch repeats recognize substrates. Published cytogenetic notation varies between older 16q24.1 and current 16q23.2 annotation; contemporary genome-build coordinates should be used for implementation. (shirakaki2022geneticapproachesfor pages 6-7, bharuchagoebel2024intrathecalgenetherapy pages 3-5, renganathan2023gigaxoninisrequired pages 1-2)

Variant interpretation. Variants are constitutional/germline, not somatic cancer drivers. Clinical classification requires ACMG/AMP evaluation using segregation, population frequency, predicted loss of function, functional evidence, and phenotype specificity. Disease-causing alleles are generally absent or extremely rare in population databases, but no comprehensive per-variant gnomAD table was available from the retrieved literature. Therefore, a blanket numerical allele frequency should not be assigned. In the German cohort, eight homozygous variants were found; the paper’s classifications included pathogenic, likely pathogenic, and VUS alleles. Molecular diagnosis should not treat a VUS alone as definitive without additional evidence. (gangfuss2025giantaxonalneuropathy pages 6-8)

Genotype–phenotype relationship. Earlier literature found weak or absent global correlation. Some cohorts suggest truncating/nonsense alleles more often produce classical severe disease and selected missense alleles milder CMT-like disease, but exceptions occur; this is not yet a reliable individual prognostic rule. (gangfuss2025giantaxonalneuropathy pages 6-8, lienard2026diseasemutationin pages 1-2)

Chromosomal, epigenetic, and modifier findings. No recurrent aneuploidy, translocation, inversion, pathogenic repeat expansion, mitochondrial-DNA defect, or disease-specific methylation signature is established. O-GlcNAcylation is a post-translational metabolic regulator, not a validated epigenetic diagnostic marker. (chen2020gigaxoninglycosylationregulates pages 2-3)

5. Environmental information

No causal toxin, radiation exposure, pollutant, occupational factor, smoking pattern, alcohol exposure, diet, or infectious agent has been demonstrated. Accordingly, CTD-style chemical causation and NCBI Taxonomy pathogen annotations are not applicable. Activity, nutrition, and respiratory-infection avoidance affect general health and complication burden, but do not prevent the underlying Mendelian disorder.

6. Mechanism and pathophysiology

Causal chain

Upstream genetic trigger: biallelic GAN loss-of-function variants reduce functional gigaxonin.
E3-ligase failure: defective CUL3–RBX1–gigaxonin substrate recognition/ubiquitylation decreases turnover of intermediate-filament proteins and other substrates.
Proteostasis/cytoskeletal disruption: NEFL, INA, peripherin, vimentin, desmin and related filaments accumulate; the CRL3-gigaxonin pathway also targets actin-associated TPM1, TPM2, TAGLN and CNN2. (lienard2026diseasemutationin pages 1-2, park2023thecrl3gigaxoninubiquitin pages 1-2)
Transport failure: loss of gigaxonin inhibits kinesin-1-mediated intermediate-filament transport. GAN-knockout cells showed a greater than 20-fold increase in soluble vimentin oligomers; direct coupling of kinesin to filaments rescued abnormal distribution, supporting transport failure as causal rather than merely secondary. (renganathan2023gigaxoninisrequired pages 1-2)
Autophagy impairment: gigaxonin normally governs ATG16L1 turnover and autophagosome production. Neurofilament aggregates subsequently disturb autophagic-organelle distribution and lysosome fusion and sequester 14-3-3, impairing TFEB localization—creating a feed-forward proteostasis defect. (paumier2024neurofilamentaccumulationdisrupts pages 1-5, shirakaki2022geneticapproachesfor pages 6-7)
Organelle/metabolic stress: aggregates impede mitochondrial motility and increase energetic demand. This is strongest in cellular and mouse-neuron evidence, not yet a validated circulating metabolomic signature. (israeli2016intermediatefilamentaggregates pages 6-7)
Tissue pathology: densely packed filaments enlarge axons, thin/disrupt myelin, impair conduction and promote axonal and neuronal loss; neuroinflammation appears downstream in overt mouse models. (shirakaki2022geneticapproachesfor pages 2-4, nath2023anewmouse pages 1-2)
Clinical expression: length-dependent sensorimotor neuropathy produces distal weakness, sensory ataxia and areflexia; cerebellar/white-matter and cranial involvement produces ataxia, cognitive, ocular and bulbar features; respiratory neuromuscular decline contributes to death.

Recent 2023 mechanistic advances. Park et al. identified a CRL3-gigaxonin–USP15 axis controlling NEFL and INA and a NEFL degron, while Renganathan et al. demonstrated the intermediate-filament transport defect. These extend the model beyond passive accumulation to active defects in substrate destruction and spatial cytoskeletal trafficking. (park2023thecrl3gigaxoninubiquitin pages 1-2, renganathan2023gigaxoninisrequired pages 1-2)

Molecular profiling. White-blood-cell proteomics from four German patients identified 111 dysregulated proteins—22 increased and 89 decreased—including proteins involved in synaptic function, filament organization, autophagosome maturation, endosome–lysosome transport, actin organization, translation, muscle contraction, SNARE/sortilin/VAMP trafficking and HYOU1/GRP170. This is exploratory, small-sample proteomics, not a validated diagnostic biomarker. (gangfuss2025giantaxonalneuropathy pages 5-6, gangfuss2025giantaxonalneuropathy pages 6-8)

No robust disease-specific single-cell atlas, spatial transcriptomic map, human CNS multi-omic integration, lipidomic signature, or clinical CRISPR-screen result was identified.

Suggested GO biological-process terms: protein ubiquitination (GO:0016567); proteasome-mediated ubiquitin-dependent protein catabolic process (GO:0043161); intermediate filament organization (GO:0045109); neurofilament bundle assembly (GO:0033693); microtubule-based transport (GO:0099111); autophagosome assembly (GO:0000045); autophagy (GO:0006914); axonal transport (GO:0098930); regulation of mitochondrial transport; neuron death (GO:0070997).

Suggested GO cellular components: intermediate filament cytoskeleton (GO:0045111); neurofilament (GO:0005883); axon (GO:0030424); autophagosome (GO:0005776); lysosome (GO:0005764); mitochondrion (GO:0005739); Cul3-RING ubiquitin ligase complex.

Suggested CL terms: neuron CL:0000540; motor neuron CL:0000100; sensory neuron CL:0000101; Schwann cell CL:0002573; oligodendrocyte CL:0000128; astrocyte CL:0000127; skeletal muscle cell CL:0000188; fibroblast CL:0000057; leukocyte CL:0000738.

7. Anatomical structures affected

Primary organ/system: peripheral nerves, spinal roots, spinal cord, brain white matter, cerebellum, and long central tracts.
Cells: long motor and sensory axons are especially vulnerable; neuronal cell bodies, Schwann cells, glia, fibroblasts, muscle and hair-associated cells show broader intermediate-filament pathology. AAV treatment was designed to reach anterior-horn motor neurons and dorsal-root-ganglion sensory neurons. (bharuchagoebel2024intrathecalgenetherapy pages 3-5)
Secondary involvement: skeletal muscle atrophy from denervation; respiratory muscles and swallowing apparatus; optic/retinal pathways and ocular lens; autonomic pathways; skin/hair.
Subcellular sites: cytoplasmic intermediate-filament networks, axon cytoskeleton, microtubule transport machinery, ubiquitin–proteasome system, autophagosomes, lysosomes, and mitochondria.
Localization/lateralization: typically bilateral and relatively symmetric, with length-dependent distal predominance; no characteristic unilateral pattern.

Suggested UBERON terms: peripheral nerve UBERON:0001021; spinal cord UBERON:0002240; brain white matter UBERON:0002316; cerebellum UBERON:0002037; dorsal root ganglion UBERON:0000044; skeletal muscle organ UBERON:0001630; sural nerve (use current UBERON/FMA release mapping); retina UBERON:0000966.

8. Temporal development

Typical onset is insidious at approximately 3–5 years, often as clumsiness, falls, sensory ataxia, or distal weakness. Classical disease progresses continuously from distal sensorimotor neuropathy to proximal and upper-limb weakness, cerebellar/bulbar and visual involvement, loss of ambulation around 8–10 years in older descriptions or later in some contemporary patients, and ventilatory/feeding dependence during the second decade. Death commonly occurs in the second or third decade. (NCT02362438 chunk 1, bharuchagoebel2024intrathecalgenetherapy pages 3-5, renganathan2023gigaxoninisrequired pages 1-2)

A slower CMT-like form preserves ambulation longer and may show less extensive MRI disease. There is no established remission or relapsing-remitting course. GAN is lifelong and progressive. The likely therapeutic window is before extensive irreversible axonal loss; trial materials explicitly prioritized younger, milder, independently ambulant patients as having greater potential to benefit. (NCT02362438 chunk 1)

9. Inheritance and population

Inheritance is autosomal recessive. For two carrier parents, each pregnancy has a 25% probability of an affected child, 50% of an unaffected carrier, and 25% of an unaffected non-carrier. Penetrance for confirmed biallelic pathogenic loss-of-function genotypes appears high, but expressivity and progression vary. Anticipation is not expected. Germline mosaicism is theoretically possible but not established as a recurrent feature.

GAN has been reported across diverse ancestries and regions; consanguinity and founder alleles can elevate local occurrence, but no ethnicity-specific population prevalence is robustly quantified. Approximately 75–80 families worldwide were cited in recent research. There are no defensible incidence or prevalence rates per 100,000, carrier-frequency estimates, or sex-ratio estimates from population registries. Both sexes are affected, consistent with autosomal inheritance. (gangfuss2025giantaxonalneuropathy pages 1-2, lienard2026diseasemutationin pages 1-2, bharuchagoebel2024intrathecalgenetherapy pages 3-5)

10. Diagnostics

Recommended approach

Recognize childhood progressive, length-dependent sensorimotor neuropathy—especially with sensory ataxia, areflexia, CNS/cerebellar signs, and tightly curled hair.
Perform neurologic, developmental, ophthalmologic, respiratory, swallowing, nutritional, and orthopedic assessment.
Obtain nerve-conduction studies and EMG. Typical findings include very low/absent SNAPs, reduced CMAPs, chronic denervation and initially normal-to-moderately reduced conduction velocity, sometimes reaching demyelinating ranges later. (shirakaki2022geneticapproachesfor pages 1-2, shirakaki2022geneticapproachesfor pages 2-4)
Brain/spinal MRI may show periventricular and cerebellar white-matter T2 hyperintensity, including around the dentate nuclei, internal capsule and spinal pathways. Magnetic-resonance spectroscopy may show reduced N-acetylaspartate. (shirakaki2022geneticapproachesfor pages 2-4, shirakaki2022geneticapproachesfor pages 4-6)
Confirm with biallelic pathogenic/likely pathogenic GAN variants and parental segregation where possible. Trial eligibility required pathogenic variants on both copies. (NCT02362438 chunk 2)
Biopsy is now supportive rather than mandatory when molecular results are definitive. Sural nerve/skin/muscle electron microscopy shows giant axons packed with disorganized neurofilaments, reduced microtubules and thin myelin. (shirakaki2022geneticapproachesfor pages 2-4)

Genetic testing

Preferred: inherited-neuropathy/neurodegeneration panel containing GAN, with deletion/duplication analysis, or WES/WGS when the phenotype is atypical or the panel is negative.
Single-gene GAN sequencing: appropriate for a highly characteristic phenotype or familial cascade testing.
WGS: useful for noncoding, structural, or difficult-to-detect alleles after negative conventional testing, although disease-specific diagnostic-yield statistics are unavailable.
RNA sequencing: potentially helpful for suspected splice variants, but not routine or validated as a GAN biomarker.
CMA/karyotype/FISH: low yield unless syndromic copy-number or cytogenetic disease is independently suspected.
Mitochondrial-DNA and repeat-expansion testing: not GAN tests; reserve for differential diagnosis.

Differential diagnosis

Consider CMT and other hereditary motor-sensory neuropathies, infantile neuroaxonal dystrophy/PLA2G6-associated neurodegeneration, hereditary spastic paraplegias, Friedreich ataxia, metachromatic leukodystrophy, Krabbe disease, mitochondrial neuropathies, neurofilament-related neuropathies, and acquired inflammatory/toxic neuropathies. GAN is distinguished by biallelic GAN variants plus combined PNS/CNS disease and giant-axon/intermediate-filament pathology.

No population or newborn-screening program exists. Cascade testing of relatives is appropriate after molecular confirmation.

11. Outcome and prognosis

Classical GAN causes major lifelong disability, usually wheelchair dependence in the second decade, progressive arm, bulbar and respiratory dysfunction, and premature mortality—often from pulmonary complications—by the third decade. Milder CMT-like cases can survive and walk longer. No reliable 5- or 10-year survival curves, mortality rate, or validated prognostic calculator exists. (shirakaki2022geneticapproachesfor pages 1-2, bharuchagoebel2024intrathecalgenetherapy pages 3-5)

The pivotal trial quantified untreated motor decline at a mean −7.17 MFM-32 percentage points/year (95% credible interval −8.36 to −5.97). This is valuable as a trial benchmark but comes from a small selected cohort rather than a population registry. (bharuchagoebel2024intrathecalgenetherapy pages 1-3)

Potential adverse prognostic features include early severe weakness, rapid MFM-32 decline, extensive CNS/MRI disease, respiratory compromise, and null/CRIM-negative genotypes, but none forms a validated multivariable model. There is no validated prognostic blood, CSF, proteomic, or imaging biomarker.

12. Treatment

Current care

There is no approved disease-modifying therapy. Management is multidisciplinary and individualized: physical/aquatic therapy; range-of-motion work and contracture prevention; orthotics, mobility devices and wheelchair/seating support; occupational and speech therapy; pain management; nutritional and swallowing assessment; feeding-tube support where required; cough assistance, pulmonary-function surveillance and noninvasive/invasive ventilation; scoliosis and orthopedic management; ophthalmologic care; and psychosocial/palliative support. (shirakaki2022geneticapproachesfor pages 1-2, NCT02362438 chunk 1, shirakaki2022geneticapproachesfor pages 8-10)

Suggested NCIt concepts include Physical Therapy, Occupational Therapy, Speech Therapy, Orthotic Device, Noninvasive Ventilation, Mechanical Ventilation, Gastrostomy, Nutritional Support, Genetic Counseling, and Palliative Care; exact NCIt codes should be resolved against the current NCIt release.

Intrathecal GAN gene replacement—2024 pivotal development

The open-label, nonrandomized phase 1 NCT02362438 study administered one intrathecal dose of scAAV9/JeT-GAN, containing a codon-optimized GAN transgene under the JeT promoter, to 14 participants. Doses were 3.5×10^13 vg (n=2), 1.2×10^14 (n=4), 1.8×10^14 (n=5), and 3.5×10^14 (n=3). (NCT02362438 chunk 1, bharuchagoebel2024intrathecalgenetherapy pages 1-3)

Over a median 68.7 months, 48 serious adverse events occurred; one—fever—was considered possibly treatment-related. Of 682 total adverse events, 129 were possibly treatment-related. Posterior probabilities of slowing one-year MFM-32 decline were 44%, 92%, 99%, and 90% across ascending doses; only the 1.8×10^14-vg group crossed the prespecified 95% efficacy threshold. Sensory-nerve action potentials improved, stabilized, or became recordable in six participants but remained absent in eight. The authors concluded that treatment produced a possible, dose-dependent motor and electrophysiological benefit and explicitly called for further safety and efficacy studies—not that efficacy was proven. (bharuchagoebel2024intrathecalgenetherapy pages 3-5, bharuchagoebel2024intrathecalgenetherapy pages 1-3)

Direct abstract quote (published 21 March 2024, PMID 38507752, DOI/URL: https://doi.org/10.1056/NEJMoa2307952): “Intrathecal gene transfer with scAAV9/JeT-GAN for giant axonal neuropathy was associated with adverse events and resulted in a possible benefit in motor function scores and other measures at some vector doses over a year.” (bharuchagoebel2024intrathecalgenetherapy pages 3-5)

Participants received glucocorticoid immunomodulation; CRIM-negative participants also received rapamycin and tacrolimus to reduce anti-transgene T-cell responses. AAV-associated dorsal-root-ganglion toxicity remains an expert concern, and the study was small, uncontrolled, dose-escalating, and compared post-treatment slopes with within-cohort pretreatment natural history. It therefore does not establish approval-level efficacy. (bharuchagoebel2024intrathecalgenetherapy pages 5-7, shirakaki2022geneticapproachesfor pages 8-10)

No validated small molecule, ASO, siRNA, mRNA, CRISPR editing, cell therapy, immunotherapy, or pharmacogenomic treatment is available. Experimental substrate-directed approaches—potentially targeting USP15, filament accumulation, autophagy or transport—remain preclinical.

13. Prevention

The disorder cannot currently be prevented through vaccination, diet, exposure avoidance, or prophylactic medication.

Primary prevention/reproductive options: carrier testing for relatives after the familial variants are known; partner testing; preimplantation genetic testing for monogenic disease; and prenatal diagnosis by chorionic-villus sampling or amniocentesis.
Secondary prevention: early molecular diagnosis and cascade testing permit surveillance and potentially earlier trial enrollment, but no newborn screening is available.
Tertiary prevention: respiratory vaccination according to routine schedules, prompt infection care, pulmonary surveillance, aspiration-risk management, contracture prevention, nutrition, mobility support, pressure-injury prevention and orthopedic monitoring can reduce complications but do not alter the genotype.
Counseling: explain autosomal-recessive recurrence risks, variable expressivity, limitations of VUS interpretation, and the experimental status and immune/toxicity uncertainties of gene therapy.

14. Other species and natural disease

No well-substantiated naturally occurring, breed-associated veterinary GAN caused by orthologous GAN variants was identified in the retrieved evidence; therefore no VBO breed term or zoonotic annotation should be assigned. GAN is neither infectious nor transmissible, and zoonotic potential is not applicable.

Orthologous gigaxonin biology is highly conserved in vertebrates, enabling engineered mouse, rat and zebrafish systems. Natural disease evidence should be kept separate from induced models. Taxa commonly used include Mus musculus (NCBI Taxon 10090), Rattus norvegicus (10116), Danio rerio (7955), and human cellular systems (9606).

15. Model organisms and experimental systems

Mouse

Conventional Gan-knockout mice reproduce intermediate-filament accumulation, Schwann-cell and peripheral-nerve pathology, transport/autonomic abnormalities and provide gene-transfer proof of concept, but early models often lacked the dramatic giant axons and severe clinical course of human GAN. Intrathecal scAAV9/JeT-GAN transduced dorsal-root ganglia, reduced filament aggregates and nerve pathology, and rescued rotarod deficits, supporting clinical translation. (bharuchagoebel2024intrathecalgenetherapy pages 3-5, shirakaki2022geneticapproachesfor pages 8-10)

The 2023 Gan−/−;TgPer model combines Gan deletion with peripherin overexpression. It developed early sensorimotor deficits, spinal-neuron swelling and brain inclusions; by 12 months it had cognitive and severe motor/sensory deficits, neuroinflammation, cortical/spinal neuron loss, and dorsal/ventral-root giant axons at least 160 μm². This supports neurofilament disorganization as a driver, but peripherin overexpression is an artificial sensitizing lesion and may exaggerate one pathway. (nath2023anewmouse pages 1-2)

Direct abstract quote (published 31 May 2023, DOI/URL: https://doi.org/10.1523/JNEUROSCI.1959-22.2023): “These results, obtained with both sexes, support the view that the disorganization of IFs can drive some neurodegenerative changes caused by gigaxonin deficiency.” (nath2023anewmouse pages 1-2)

A disease-allele GANA49E/A49E mouse reported sensorimotor deficits, ataxia, giant axons, demyelination and neurofilament disorganization and may model human missense disease more faithfully than a complete knockout. (lienard2026diseasemutationin pages 1-2)

Rat and other vertebrate models

Gan-deficient rats demonstrate extensive rod and cone photoreceptor degeneration and early ocular-lens pathology, broadening recognition of ocular disease and informing whether CNS-directed treatment alone is sufficient. PMID 33955818 and PMID 30709364 are cited in the clinical-trial record. (NCT02362438 chunk 2)

Zebrafish knockdown/mutant systems have been used to study gigaxonin-dependent motility and nervous-system development, but detailed quantitative phenotype evidence was not recovered here; they are best considered rapid developmental and screening models rather than complete natural-history replicas.

Human cellular models

Patient fibroblasts, CRISPR GAN-null neuroblastoma/fibroblast lines, dorsal-root-ganglion neurons, and patient-derived iPSC motor neurons reproduce intermediate-filament accumulation. Restoration of gigaxonin rescues filament pathology, providing target validation and platforms for vector, substrate and small-molecule testing. CRISPR GAN-null cells were also used to study O-GlcNAc regulation, and live-cell photoconversion systems resolved kinesin-dependent filament transport. (chen2020gigaxoninglycosylationregulates pages 2-3, renganathan2023gigaxoninisrequired pages 1-2, shirakaki2022geneticapproachesfor pages 11-12)

Direct abstract quote from the 2023 transport study (DOI/URL: https://doi.org/10.1096/fj.202202119R): “The loss of gigaxonin dramatically inhibited transport of IFs along microtubules by the microtubule motor kinesin-1.” (renganathan2023gigaxoninisrequired pages 1-2)

Knowledge-base conclusions

GAN1 is a high-penetrance recessive axonopathy caused by loss of gigaxonin-dependent cytoskeletal proteostasis. The strongest current causal chain is GAN loss of function → defective CRL3 substrate ubiquitylation and filament transport/autophagy → intermediate-filament accumulation → giant axons, impaired organelle transport and axonal degeneration → progressive peripheral and central neurologic disability. Human evidence supports characteristic early childhood onset, severe functional decline and premature pulmonary mortality, but population epidemiology, standardized quality-of-life data, validated biomarkers, protective factors, modifier genes, and definitive genotype–prognosis rules remain absent. The 2024 intrathecal AAV9 trial is the principal translational advance: it demonstrated feasibility, long follow-up and a possible motor benefit at selected doses, while leaving efficacy, optimal dose, durability, immune management and dorsal-root-ganglion safety unresolved. (park2023thecrl3gigaxoninubiquitin pages 1-2, bharuchagoebel2024intrathecalgenetherapy pages 3-5, bharuchagoebel2024intrathecalgenetherapy pages 1-3, renganathan2023gigaxoninisrequired pages 1-2)

References

(shirakaki2022geneticapproachesfor pages 1-2): Satomi Shirakaki, Rohini Roy Roshmi, and Toshifumi Yokota. Genetic approaches for the treatment of giant axonal neuropathy. Journal of Personalized Medicine, 13:91, Dec 2022. URL: https://doi.org/10.3390/jpm13010091, doi:10.3390/jpm13010091. This article has 4 citations.
(gangfuss2025giantaxonalneuropathy pages 1-2): Andrea Gangfuß, Guido Goj, Silke Polz, Adela Della Marina, Andreas Hentschel, Katja Ahlbory, Timo Deba, Urania Kotzaeridou, Elisabeth Schuler, Astrid Pechmann, Uta Diebold, Gerhard Kurlemann, Lucas Heinzkyll, Dirk Schmitt, Kevin Rostasy, Tobias Ruck, Johann Böhm, Andreas Roos, and Ulrike Schara-Schmidt. Giant axonal neuropathy (gan): cross-sectional data on phenotypes, genotypes, and proteomic signature from a german cohort. Journal of Neurology, Dec 2025. URL: https://doi.org/10.1007/s00415-024-12744-z, doi:10.1007/s00415-024-12744-z. This article has 4 citations and is from a domain leading peer-reviewed journal.
(NCT02362438 chunk 1): Intrathecal Administration of scAAV9/JeT-GAN for the Treatment of Giant Axonal Neuropathy. National Institute of Neurological Disorders and Stroke (NINDS). 2015. ClinicalTrials.gov Identifier: NCT02362438
(NCT02362438 chunk 3): Intrathecal Administration of scAAV9/JeT-GAN for the Treatment of Giant Axonal Neuropathy. National Institute of Neurological Disorders and Stroke (NINDS). 2015. ClinicalTrials.gov Identifier: NCT02362438
(bharuchagoebel2024intrathecalgenetherapy pages 1-3): Diana X. Bharucha-Goebel, Joshua J. Todd, Dimah Saade, Gina Norato, Minal Jain, Tanya Lehky, Rachel M. Bailey, Jessica A. Chichester, Roberto Calcedo, Diane Armao, A. Reghan Foley, Payam Mohassel, Eshetu Tesfaye, Bradley P. Carlin, Beth Seremula, Melissa Waite, Wadih M. Zein, Laryssa A. Huryn, Thomas O. Crawford, Charlotte J. Sumner, Ahmet Hoke, John D. Heiss, Lawrence Charnas, Jody E. Hooper, Thomas W. Bouldin, Elizabeth M. Kang, Denis Rybin, Steven J. Gray, and Carsten G. Bönnemann. Intrathecal gene therapy for giant axonal neuropathy. The New England journal of medicine, 390 12:1092-1104, Mar 2024. URL: https://doi.org/10.1056/nejmoa2307952, doi:10.1056/nejmoa2307952. This article has 69 citations and is from a highest quality peer-reviewed journal.
(gangfuss2025giantaxonalneuropathy pages 5-6): Andrea Gangfuß, Guido Goj, Silke Polz, Adela Della Marina, Andreas Hentschel, Katja Ahlbory, Timo Deba, Urania Kotzaeridou, Elisabeth Schuler, Astrid Pechmann, Uta Diebold, Gerhard Kurlemann, Lucas Heinzkyll, Dirk Schmitt, Kevin Rostasy, Tobias Ruck, Johann Böhm, Andreas Roos, and Ulrike Schara-Schmidt. Giant axonal neuropathy (gan): cross-sectional data on phenotypes, genotypes, and proteomic signature from a german cohort. Journal of Neurology, Dec 2025. URL: https://doi.org/10.1007/s00415-024-12744-z, doi:10.1007/s00415-024-12744-z. This article has 4 citations and is from a domain leading peer-reviewed journal.
(gangfuss2025giantaxonalneuropathy pages 6-8): Andrea Gangfuß, Guido Goj, Silke Polz, Adela Della Marina, Andreas Hentschel, Katja Ahlbory, Timo Deba, Urania Kotzaeridou, Elisabeth Schuler, Astrid Pechmann, Uta Diebold, Gerhard Kurlemann, Lucas Heinzkyll, Dirk Schmitt, Kevin Rostasy, Tobias Ruck, Johann Böhm, Andreas Roos, and Ulrike Schara-Schmidt. Giant axonal neuropathy (gan): cross-sectional data on phenotypes, genotypes, and proteomic signature from a german cohort. Journal of Neurology, Dec 2025. URL: https://doi.org/10.1007/s00415-024-12744-z, doi:10.1007/s00415-024-12744-z. This article has 4 citations and is from a domain leading peer-reviewed journal.
(NCT01503125 chunk 1): Giant Axonal Neuropathy Natural History Study. Columbia University. 2011. ClinicalTrials.gov Identifier: NCT01503125
(shirakaki2022geneticapproachesfor pages 2-4): Satomi Shirakaki, Rohini Roy Roshmi, and Toshifumi Yokota. Genetic approaches for the treatment of giant axonal neuropathy. Journal of Personalized Medicine, 13:91, Dec 2022. URL: https://doi.org/10.3390/jpm13010091, doi:10.3390/jpm13010091. This article has 4 citations.
(shirakaki2022geneticapproachesfor pages 4-6): Satomi Shirakaki, Rohini Roy Roshmi, and Toshifumi Yokota. Genetic approaches for the treatment of giant axonal neuropathy. Journal of Personalized Medicine, 13:91, Dec 2022. URL: https://doi.org/10.3390/jpm13010091, doi:10.3390/jpm13010091. This article has 4 citations.
(bharuchagoebel2024intrathecalgenetherapy pages 3-5): Diana X. Bharucha-Goebel, Joshua J. Todd, Dimah Saade, Gina Norato, Minal Jain, Tanya Lehky, Rachel M. Bailey, Jessica A. Chichester, Roberto Calcedo, Diane Armao, A. Reghan Foley, Payam Mohassel, Eshetu Tesfaye, Bradley P. Carlin, Beth Seremula, Melissa Waite, Wadih M. Zein, Laryssa A. Huryn, Thomas O. Crawford, Charlotte J. Sumner, Ahmet Hoke, John D. Heiss, Lawrence Charnas, Jody E. Hooper, Thomas W. Bouldin, Elizabeth M. Kang, Denis Rybin, Steven J. Gray, and Carsten G. Bönnemann. Intrathecal gene therapy for giant axonal neuropathy. The New England journal of medicine, 390 12:1092-1104, Mar 2024. URL: https://doi.org/10.1056/nejmoa2307952, doi:10.1056/nejmoa2307952. This article has 69 citations and is from a highest quality peer-reviewed journal.
(renganathan2023gigaxoninisrequired pages 1-2): Bhuvanasundar Renganathan, James P Zewe, Yuan Cheng, Mark Kittisopikul, Puneet Opal, Karen M Ridge, and Vladimir I. Gelfand. Gigaxonin is required for intermediate filament transport. The FASEB Journal, Aug 2023. URL: https://doi.org/10.1096/fj.202202119r, doi:10.1096/fj.202202119r. This article has 20 citations.
(NCT02362438 chunk 2): Intrathecal Administration of scAAV9/JeT-GAN for the Treatment of Giant Axonal Neuropathy. National Institute of Neurological Disorders and Stroke (NINDS). 2015. ClinicalTrials.gov Identifier: NCT02362438
(chen2020gigaxoninglycosylationregulates pages 2-3): Po-Han Chen, Jimin Hu, Jianli Wu, Duc T. Huynh, Timothy J. Smith, Samuel Pan, Brittany J. Bisnett, Alexander B. Smith, Annie Lu, Brett M. Condon, Jen-Tsan Chi, and Michael Boyce. Gigaxonin glycosylation regulates intermediate filament turnover and may impact giant axonal neuropathy etiology or treatment. JCI insight, Jan 2020. URL: https://doi.org/10.1172/jci.insight.127751, doi:10.1172/jci.insight.127751. This article has 21 citations and is from a domain leading peer-reviewed journal.
(shirakaki2022geneticapproachesfor pages 6-7): Satomi Shirakaki, Rohini Roy Roshmi, and Toshifumi Yokota. Genetic approaches for the treatment of giant axonal neuropathy. Journal of Personalized Medicine, 13:91, Dec 2022. URL: https://doi.org/10.3390/jpm13010091, doi:10.3390/jpm13010091. This article has 4 citations.
(nath2023anewmouse pages 1-2): Banshi Nath and Jean-Pierre Julien. A new mouse model of giant axonal neuropathy with overt phenotypes and neurodegeneration driven by neurofilament disorganization. The Journal of Neuroscience, 43:4174-4189, May 2023. URL: https://doi.org/10.1523/jneurosci.1959-22.2023, doi:10.1523/jneurosci.1959-22.2023. This article has 6 citations.
(park2023thecrl3gigaxoninubiquitin pages 1-2): Hyoung-Min Park, Ly Le, Thao T. Nguyen, Ki Hong Nam, Alban Ordureau, J. Eugene Lee, and Thang Van Nguyen. The crl3gigaxonin ubiquitin ligase–usp15 pathway governs the destruction of neurofilament proteins. Proceedings of the National Academy of Sciences of the United States of America, Oct 2023. URL: https://doi.org/10.1073/pnas.2306395120, doi:10.1073/pnas.2306395120. This article has 11 citations and is from a highest quality peer-reviewed journal.
(bharuchagoebel2024intrathecalgenetherapy pages 5-7): Diana X. Bharucha-Goebel, Joshua J. Todd, Dimah Saade, Gina Norato, Minal Jain, Tanya Lehky, Rachel M. Bailey, Jessica A. Chichester, Roberto Calcedo, Diane Armao, A. Reghan Foley, Payam Mohassel, Eshetu Tesfaye, Bradley P. Carlin, Beth Seremula, Melissa Waite, Wadih M. Zein, Laryssa A. Huryn, Thomas O. Crawford, Charlotte J. Sumner, Ahmet Hoke, John D. Heiss, Lawrence Charnas, Jody E. Hooper, Thomas W. Bouldin, Elizabeth M. Kang, Denis Rybin, Steven J. Gray, and Carsten G. Bönnemann. Intrathecal gene therapy for giant axonal neuropathy. The New England journal of medicine, 390 12:1092-1104, Mar 2024. URL: https://doi.org/10.1056/nejmoa2307952, doi:10.1056/nejmoa2307952. This article has 69 citations and is from a highest quality peer-reviewed journal.
(shirakaki2022geneticapproachesfor pages 8-10): Satomi Shirakaki, Rohini Roy Roshmi, and Toshifumi Yokota. Genetic approaches for the treatment of giant axonal neuropathy. Journal of Personalized Medicine, 13:91, Dec 2022. URL: https://doi.org/10.3390/jpm13010091, doi:10.3390/jpm13010091. This article has 4 citations.
(lienard2026diseasemutationin pages 1-2): Caroline Liénard, Nicolas Pradeilles, Elisabeth Cortier, Cedric Hassen-Khodja, Leticia Arias, Maria Ceprian-Costoso, Antoine Picot, Anne-Laure Mausset-Bonnefont, Chantal Cazevieille, Frederic Fiore, and Pascale Bomont. Disease mutation in gigaxonin-e3 ligase recapitulates giant axonal neuropathy in mice. Acta Neuropathologica Communications, Dec 2025. URL: https://doi.org/10.1186/s40478-025-02138-1, doi:10.1186/s40478-025-02138-1. This article has 0 citations and is from a peer-reviewed journal.
(shirakaki2022geneticapproachesfor pages 11-12): Satomi Shirakaki, Rohini Roy Roshmi, and Toshifumi Yokota. Genetic approaches for the treatment of giant axonal neuropathy. Journal of Personalized Medicine, 13:91, Dec 2022. URL: https://doi.org/10.3390/jpm13010091, doi:10.3390/jpm13010091. This article has 4 citations.
(paumier2024neurofilamentaccumulationdisrupts pages 1-5): Jean-Michel Paumier, James Zewe, Melissa R Pergande, Meghana Venkatesan, Eitan Israeli, Chiranjit Panja, Natasha Snider, Jeffrey Savas, and Puneet Opal. Neurofilament accumulation disrupts autophagy in giant axonal neuropathy. JCI Insight, Mar 2025. URL: https://doi.org/10.1101/2024.03.29.587353, doi:10.1101/2024.03.29.587353. This article has 6 citations and is from a domain leading peer-reviewed journal.
(israeli2016intermediatefilamentaggregates pages 6-7): Eitan Israeli, Dilyan I. Dryanovski, Paul T. Schumacker, Navdeep S. Chandel, Jeffrey D. Singer, Jean P. Julien, Robert D. Goldman, and Puneet Opal. Intermediate filament aggregates cause mitochondrial dysmotility and increase energy demands in giant axonal neuropathy. Human molecular genetics, 25 11:2143-2157, Mar 2016. URL: https://doi.org/10.1093/hmg/ddw081, doi:10.1093/hmg/ddw081. This article has 61 citations and is from a domain leading peer-reviewed journal.

Artifacts

Edison artifact artifact-00

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome	Count
References checked	13
Resolved	13
Unresolved (possible confabulation)	0
Unverifiable	0
References weighed for topical relevance	13
On topic	9
Off topic	0

All extracted references resolved successfully.

Ask OpenScientist

OpenScientist Report

Mappings

Inheritance

Subtypes

Discussions and Knowledge Gaps

Pathophysiology

Histopathology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Diagnosis

Prevalence

Clinical Trials

Experimental Models

Animal Models

Source YAML

References & Deep Research

References

Deep Research

Disease Characteristics Research Template

Target Disease

Research Objectives

1. Disease Information

2. Etiology

3. Phenotypes

4. Genetic/Molecular Information

5. Environmental Information

6. Mechanism / Pathophysiology

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

10. Diagnostics

11. Outcome/Prognosis

12. Treatment

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Citation Requirements

Output Format

Giant Axonal Neuropathy 1 (GAN1): comprehensive disease-characteristics report

1. Disease information

2. Etiology

Causal and genetic factors

Risk, protective, and modifying factors

3. Phenotypes

4. Genetic and molecular information

5. Environmental information

6. Mechanism and pathophysiology

Causal chain

7. Anatomical structures affected

8. Temporal development

9. Inheritance and population

10. Diagnostics

Recommended approach

Genetic testing

Differential diagnosis

11. Outcome and prognosis

12. Treatment

Current care

Intrathecal GAN gene replacement—2024 pivotal development

13. Prevention

14. Other species and natural disease

15. Model organisms and experimental systems

Mouse

Rat and other vertebrate models

Human cellular models

Knowledge-base conclusions

Artifacts

Reference Validation